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SOMMARIO  
 
I vaccini rappresentano senza dubbio l’arma più efficace per combattere e tenere 
sotto controllo le infezioni [1]. In aggiunta agli antigeni del patogeno, i vaccini 
contengono adiuvanti utilizzati per potenziare le risposte immunitarie specifiche 
verso determinati antigeni. Nonostante la loro efficacia e il loro largo uso, il 
meccanismo di azione di molti adiuvanti è ancora scarsamente caratterizzato [2]. 
Pertanto, far luce sui meccanismi d’azione degli adiuvanti vaccinali è fondamentale 
per sviluppare prodotti nuovi, più efficienti e sicuri, e poter così sfruttare appieno il 
potenziale della vaccinologia [3]. Dopo la vaccinazione, è stato osservato al sito di 
iniezione il rilascio locale di molecole endogene con la capacità di segnalare “danno” 
al sistema immunitario, note come allarmine. Per esempio, un rilascio locale di acido 
urico e DNA è stato osservato nel modello murino dopo vaccinazione con alum, il 
più diffuso tra gli adiuvanti approvati per uso sull’uomo. Tuttavia, finora non è mai 
stato esplorato un potenziale ruolo dell’ATP durante la vaccinazione. L’ATP, tra le 
sue tante funzioni, quando rilasciato nell’ambiente extracellulare in concentrazioni 
opportune può fungere da allarmina e, come tale è un forte modulatore delle risposte 
immunitarie [4-6]. Pertanto, in questo lavoro abbiamo indagato se un rilascio di ATP 
è coinvolto nel meccanismo d’azione di quattro comuni adiuvanti vaccinali: 
idrossido di alluminio (alum), calcio fosfato (CaPi), adiuvante incompleto di Freund 
(IFA) e MF59. Sono stati condotti esperimenti ex vivo su muscoli murini isolati 
(tibiale anteriore e quadricipite) e in vivo in topi immunizzati intramuscolo con 
l’adiuvante da testare e il sistema reporter luciferina-luciferasi in grado di segnalare 
il livello di ATP al sito d’iniezione. Abbiamo osservato che l'iniezione 
intramuscolare è sempre associata a un debole e transitorio rilascio di ATP. Il rilascio 
basale di ATP è notevolmente potenziato dall’iniezione di MF59 ma non dagli altri 
adiuvanti testati. 
Pertanto, abbiamo esplorato se e come il rapido e transitorio rilascio di ATP indotto 
da MF59 al sito d’iniezione potesse contribuire al suo meccanismo d’azione.  
Il forte potere adiuvante di MF59 [7, 8] è stato attribuito alla sua capacità di istituire 
un ambiente immunocompetente al sito di iniezione nel muscolo, caratterizzato da un 
rapido e transitorio afflusso di un gran numero di cellule immunitarie che captano e 
assorbono l’antigene e lo trasportano ai linfonodi drenanti [9-11]. Abbiamo qui 
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dimostrato, che la co-iniezione di apirasi, un enzima in grado di idrolizzare l’ATP, 
riduce fortemente l’afflusso di cellule immunitarie indotto da MF59 ma non quello 
indotto da alum o IFA.  
Questi risultati indicano che l’abilità di MF59 di indurre un forte afflusso di cellule 
immunitarie al sito di iniezione è in parte dovuta alla sua intrinseca capacità di 
rilasciare ATP. Inoltre, abbiamo osservato che la co-iniezione di apirasi e MF59 
riduce il numero di cellule antigene-positive che dal muscolo raggiungono i linfonodi 
drenanti. Tale riduzione si è rivelata tipo cellulare-specifica, infatti il trattamento con 
apirasi impatta negativamente il numero di cellule B antigene-positive indotto da 
MF59 nei linfonodi drenanti, suggerendo che le cellule B potrebbero essere un 
elemento chiave nei “pathways” mediati da ATP  durante la vaccinazione. 
Efficienti risposte immunitarie di tipo innato si traducono spesso in forti risposte 
adattative [12]. Pertanto, abbiamo analizzato un eventuale ruolo dell’ATP rilasciato 
da MF59 sull’attivazione delle cellule T e la produzione di titoli anticorpali antigene-
specifici. Di conseguenza, gruppi di topi sono stati immunizzati con un vaccino 
influenzale trivalente, iniettato come tale o adiuvato con MF59 con o senza apirasi. 
L’apirasi ha fortemente ridotto la proliferazione delle cellule T vaccino-specifiche e i 
relativi titoli anticorpali. Questi dati dimostrano che un locale e transitorio rilascio di 
ATP a livello del sito d’iniezione è necessario per lo sviluppo di risposte immunitarie 
innate e adattative indotte da MF59 e associano per la prima volta un rilascio 
extracellulare di ATP a un potenziamento delle risposte immunitarie indotte dalla 
vaccinazione. 
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SUMMARY  
 
Vaccines are the most effective agents to control infections [1]. In addition to the 
pathogen antigens, vaccines contain adjuvants that are used to enhance the specific 
immune responses. Despite their effectiveness and their wide use, the mechanism of 
action of many adjuvants is poorly characterized [2]. Therefore, adjuvant research is 
crucial to better understand how they work and to exploit their full potential in 
vaccinology [3]. Release of endogenous danger signals has been linked to 
adjuvanticity, however the role of extracellular ATP during vaccination has never 
been explored. Extracellular ATP can work as "danger signal" and, as such is a 
strong modulator of immune responses [4-6]. Here, we tested whether ATP release is 
involved in the immune boosting effect of four common adjuvants: aluminium 
hydroxide, calcium phosphate (CaPi), incomplete Freund’s adjuvant (IFA) and the 
squalene-based oil in water emulsion MF59.  
Experiments were performed ex vivo in excised mice muscles (tibialis anterior and 
quadriceps) and in vivo in live mice injected with the reporter system luciferase-
luciferin that reports on ATP changes. We found that intramuscular injection in 
general is always associated to a weak transient release of ATP. In contrast, a greatly 
enhanced ATP release was found upon injection of MF59 but not by all other adjuvants 
tested. 
Therefore, we wanted to dissect whether and how ATP release would contribute to 
the activity of MF59. The strong adjuvanticity of MF59 [7-8] has been ascribed to its 
capability to induce an immunocompetent environment in the muscle, characterized 
by a rapid and transient influx of a large number of immune cells participating in 
antigen uptake and transport to draining lymph nodes [9-11]. We found that the local 
injection of apyrase, an ATP-hydrolyzing enzyme, reduced the immune cells 
recruitment induced by MF59 but not by alum or IFA. These findings indicated that 
the ability of MF59 to induce migration of different immune cells into the injected 
muscle is partly due to induced ATP release. Moreover, co-injection of apyrase and 
MF59 at the muscle injection site reduces the number of antigen positive cells in the 
draining lymph nodes in a cell type-specific manner. Indeed, co-injection of apyrase 
negatively impacts the number of antigen positive B cells induced by MF59, 
suggesting that B cells could be a key component in ATP-mediated signaling during 
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vaccination. Strong innate immune responses lead to enhanced adaptive immune 
responses [12]. Accordingly, we compared the impact of MF59-induced ATP release 
on T cells responses and antibody titers. Groups of mice were immunized with an 
experimental trivalent influenza vaccine (TIV) either as plain antigens or together 
with MF59 with or without apyrase. Apyrase strongly inhibited influenza specific T 
cell responses, total IgG and hemagglutination inhibition titers in response to an 
MF59-adjuvanted trivalent influenza vaccine. These data demonstrate that a transient 
ATP release is required for innate and adaptive immune responses induced by MF59 
and link for the first time extracellular ATP to an enhanced response to vaccination. 
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1. INTRODUCTION 
 
1.1 Brief overview on the immune system 
 
Invasion of a host by pathogenic agents triggers a complex set of immune responses 
through interactions between a diverse array of pathogen-borne virulence factors and 
the immune surveillance mechanisms of the host [13]. The mammalian immune 
system comprises an innate and adaptive component. The innate immune system is 
the first line of defense against pathogens and is mediated by leukocytes including 
macrophages and dendritic cells (DCs) and by the complement system. It acts 
immediately using a limited number of germ-line-encoded pattern-recognition 
receptors (PRRs) that recognize invariant pathogen-associated molecular patterns 
(PAMPs). PRRs function as sensors that alert the immune system of an imminent 
danger. The best known members of the PRRs family are the Toll-like receptors 
(TLRs) [14]. TLRs detect foreign organisms in the extracellular space, in the 
phagosome or endosome lumen. The cytoplasm instead is surveyed by two different 
families of PRRs: the retinoic acid-inducible gene (RIG)-like helicases (RLHs) and 
the nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) [14]. 
RLHs are mainly involved in antiviral immunity. NLRs comprise the NOD proteins 
and the inflammasome scaffold proteins (IPAF, NAIP and NALPs). There is 
evidence that NLRs mediate immunity against intracellular pathogens and are 
involved in the pathogenesis of autoinflammatory diseases [15-17]. 
In contrast, the adaptive immune system, which is long lasting and has 
immunological memory, is based on a myriad of receptors, which can be soluble, 
such as the immunoglobulins, or cell-bound as T- or B-cell receptors. Because of this 
large repertoire of recognition molecules, the immune system discriminates among 
an almost countless number of antigens. Induction of adaptive immunity not only 
depends on direct antigen recognition by the antigen receptors but also relies on 
essential signals that are delivered by the innate immune system [18]. Accordingly, 
the responses of the innate immune system to pathogens help to initiate adaptive 
immune responses by different mechanisms. Microbial infection is detected by PRRs 
and their signaling leads to the activation of phagocytic cells like macrophages and 
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DCs. These cells besides phagocytosing and eliminating pathogens can also act as 
so-called Antigen-Presenting Cells (APCs). APCs like DCs, digest the phagocytosed 
pathogen to peptides, which are subsequently re-exposed on the APCs surface on 
MHCII molecules. Such, APCs transport pathogen-derived antigens to local 
lymphoid organs where they are presented to na ve T cells.  uring the encounter of 
an APC with an antigen-specific T cell, the latter will get activated and start to 
proliferate and differentiate. These effector T cells then either leave the lymphoid 
organs to affect cell-mediated immunity in sites of infection in the tissues or remain 
in the lymphoid organs to participate in humoral immunity by activating B cells [19]. 
Protective immunity against reinfection is one of the most important consequences of 
adaptive immunity operating through the clonal selection of lymphocytes. Protective 
immunity depends not only on pre-formed antibodies and effector T cells, but most 
importantly on the establishment of a population of lymphocytes that mediated long 
lived immunological memory. The capacity of these cells to respond rapidly to 
restimulation with the same antigen can be transferred to na ve recipients by primed 
B and T cells [19]. 
 
 
1.2 Regulation of the immune response: the danger theory and 
endogenous alarmins 
 
Besides the aforementioned immune activation by PRRs, the innate and adaptive 
immune system can also be activated by endogenous signals that originate from 
stressed, injured, or necrotic cells, indicating danger to the host. The danger theory 
was first postulated in 1994 as part of a model of immunity that suggests that the 
immune system responds to substances that cause damage, rather than to those that 
are simply foreign [20]. Endogenous danger signals released from necrotic or 
stressed cells which trigger the inflammatory response after trauma have been termed 
alarmins or danger-associated molecular patterns ( AMPs) [21]. Oppenheim and 
Yang have recently grouped several endogenous signals into the category of 
“alarmins” on the basis of three properties: I) they are rapidly released in response to 
infection or tissue injury; II) they have chemotactic and activating effects on APCs, 
particularly  Cs; and III) they have potent immunoenhancing activity in vivo [22, 
9 
 
23]. Alarmins not only may generate tissue inflammation after injury, but they also 
could act synergistically with microbial non-self antigens to enhance the 
inflammatory reaction. Well-known alarmins include heat shock proteins, uric acid, 
hyaluronan, monosodium urate, thioredoxin, extracellular nucleotides, mitochondrial 
 NA, high- mobility group box protein 1 (HMGB1), interleukins (such as IL- 1 and 
IL-33) and reactive oxygen species (ROS) (Table 1) [23, 24]. Moreover, host defense 
antimicrobial peptides such as B-defensins and cathelicidins [24]. 
 
 
 
 
Table 1. Example of well characterized alarmins. (Source: modified from Sa d-Sadier N & Ojcius 
 M, Biomed. J., 2012 [24]) 
 
In recent years, it has become clear that PRRs are not exclusively selective for 
PAMPs but can also be activated by DAMPs such as monosodium urate crystals and 
extracellular ATP. The most likely explanation for the presence of a dual control in 
the activation of innate immunity is that the body is continuously exposed to foreign 
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microorganisms, which are not necessarily harmful, such us commensal bacteria, and 
against which it would be even counterproductive to initiate an immune response. To 
avoid an inappropriate and potentially harmful reaction, a two-step mechanism of 
control has evolved: detection of a foreign microorganism is not sufficient to trigger 
inflammation, unless the body has unequivocal proof that this microorganism is also 
dangerous. The proof is provided by the detection of host cell damage, as assessed by 
the release of host-derived danger signals [17]. 
 
1.2.1 Endogenous danger signals: extracellular ATP 
ATP is an important signaling molecule belonging to the purine family. It is produced 
by cellular respiration and constitutes an indispensable factor for the proper function 
of a wide variety of enzymes and structural proteins. Extracellular release of ATP 
takes place in healthy tissue under different conditions, and is involved in a variety of 
cellular responses such as neurotransmission, vasodilatation, muscle contraction, and 
cell growth [25, 26]. Thus, in healthy tissues, release of ATP is tightly controlled and 
its extracellular concentration is kept low by ubiquitous ecto‑ATP/A Pases [27]. 
Intracellular nucleotides like ATP and UTP, normally stored in the cytosol, are 
released from a variety of cells under conditions of hypoxia, ischemia, inflammation 
or even mechanical stress and can activate  Cs by themselves [28].   uring tissue 
injury, trauma or cellular stress, the extracellular levels of these nucleotides can 
become elevated and are sensed as a potential threat to surrounding tissues. 
ATP mediates its effects through ligation of distinct cell‑surface purinergic P2 
receptors (P2Rs). P2Rs are divided into two families called P2Y (G protein‑coupled 
receptors) and P2X (ligand‑gated cation channels), which have distinct effector 
functions, pharmacological profiles and tissue distribution. Immune and 
inflammatory cells express P2Y and P2X receptors and their expression is modulated 
during development and by inflammatory cytokines [29]. Immune cells maintain a 
steady concentration of ATP in their pericellular environment via a complex 
mechanism of ATP release and hydrolysis, which is dependent on the activity of 
ecto-ATPases and ecto-nucleotidases.  
Extracellular ATP can accumulate in the pericellular space to concentrations 
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sufficiently high to activate P2Rs and thus modulate key responses such as 
chemotaxis, cytokine release, recruitment and activation of neutrophils, macrophages 
and dendritic cells.  
ATP can also stimulate monocyte and microglial cell migration, and has a profound 
impact on ROS and nitric oxide production [29, 30]. 
Extracellular ATP is also a well-known activator of the NLR family, pyrin domain-
containing 3 (NLRP3) inflammasome. The ATP-dependent IL‑1β release via 
NALP3 [31, 32] has been linked to the P2X7 receptor [33]. Moreover, it was shown 
that pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-
gated P2X7 receptor [34]. Extracellular ATP triggers K+ efflux, inducing gradual 
recruitment of the pannexin‑1 pore and allowing extracellular NLRP3 agonists to 
access the cytosol [34, 35]. Therefore, ATP is emerging as an important local 
regulatory factor of the immune responses and P2 receptors are identified as crucial 
molecular components in the chain of events that leads to inflammatory cell 
activation. Moreover, ATP is an important cofactor, an enhancer of the inflammatory 
reaction in response to mitochondrial danger molecules and to microbial-associated 
molecular patterns. Thus, agents that modulate the extracellular ATP concentration 
(e.g. soluble ATPases or inhibitors of plasma membrane ecto-ATPases) such as many 
agonists and antagonists of P2Rs might turn out to be potent modulators of the local 
inflammatory response and immunological events. 
 
 
1.3 Immune response to infection and the concept of vaccination 
 
Infectious diseases have been a huge issue for mankind and continue to be a 
significant medical problem today [36]. Vaccination remains the most effective 
method of preventing infectious diseases and represents the most relevant 
contribution of microbiology and immunology to human health.  
During the normal course of infection innate immune responses to pathogens, among 
their many effects, lead to a rapid production of inflammatory cytokines and 
activation of APCs, such as macrophages and dendritic cells. These responses also 
contribute to the development of specific adaptive immune responses with 
production of antibodies and effector T cells that eliminate the pathogen from the 
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body. After pathogen elimination, many of the effector T and B cells die and 
antibody levels gradually decline, because the antigens that induced the response 
have been eliminated. However, memory T and B cells remain, and maintain an 
enhanced ability to mount faster and more efficiently secondary responses against 
the same pathogen [19]. Vaccination mimics natural infection and effectively induces 
pathogen-specific adaptive immunity. The ability to generate antigen-specific 
memory, which protects against repeated infections with the same pathogens is a 
fundamental property of the adaptive immune system and determines the success of 
vaccination [37, 38].  
The concept of vaccination originated several hundred years ago from the historical 
observation that individuals who survived an infectious disease rarely got the same 
disease a second time [39, 40]. The first evidence of vaccination occurred in the 16
th
 
century in China or in India with the practice of variolation, when smallpox pustules 
from an infected patient were inoculated into healthy individuals to prevent smallpox 
[41]. Later, in the 18
th
 century, Edward Jenner used cowpox-infected materials to 
immunize against smallpox and introduced the term "vaccine" [37, 42]. More than 80 
years later, Louis Pasteur developed methods for attenuation of bacteria [38] and 
Salmon and Smith developed methods for inactivation of microorganisms. Together, 
these advances led to a new era of vaccinology. Then, after World War II the 
technology of cells grown in vitro for virus cultivation was demonstrated by Enders, 
Weller, and Robbins and then built upon by many other researchers [37]. Virus 
culture enabled the development of methods for attenuating viral vaccines and 
allowed the development of several vaccines, including inactivated polio, live polio, 
measles, mumps, rubella, adenovirus, and varicella [37]. 
By the latter part of the 20
th
 century, most of the vaccines that could be developed by 
direct mimicry of natural infection with live attenuated or killed/inactivated 
pathogens had been developed. Later, the advent of new technologies, such as 
protein conjugation to capsular polysaccharides and methods to engineer 
recombinant DNA, led to the development of vaccines for prevention of bacterial 
pneumonia and meningitis, hepatitis B, and the human papilloma virus vaccine for 
example. The success of vaccines demonstrates the potential of this approach in 
reducing the global burden of infectious diseases or even in eradicating them, as in 
the case of smallpox [43]. However, there are still several diseases that cause 
considerable global morbidity and mortality for which protective vaccines do not 
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exist [44]. Some examples are human immunodeficiency virus, mycobacterium 
tuberculosis, plasmodium falciparum, hepatitis C virus, respiratory syncytial and 
dengue virus [45-53]. Therefore a better understanding of the vaccination process is 
needed to develop novel vaccine based on molecular targets that further improve 
vaccine efficacy.  
 
 
1.4 Vaccines 
 
The first effective vaccine was developed by Jenner more than 200 years ago and 
today there are vaccines available against different viral and bacterial pathogens. It is 
easy to define the properties of an optimal vaccine (Table 2), but few vaccines 
approach the ideal [54]. 
 
 
Table 2. Properties of an ideal vaccine. (Source: modified from Beverley P.C. Br. Med. Bull., 2002 
[54]) 
 
The most broadly used vaccines are based on live attenuated or inactivated whole 
organisms. In this case, all of the antigens from the pathogen are present in the 
vaccine and all are potential targets for an immune response. Furthermore, various 
microbial components, such as immunostimulatory CpG  NA motifs, double-
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stranded RNA, and some glycolipids are known to stimulate the innate immune 
system. The presence of these PAMPs can provide the vaccine with a built-in 
“adjuvant”. The word adjuvant – originating from the latin word “adiuvare” meaning 
“to help” - refers to different substances or compounds able to enhance immune 
responses towards co-administered antigens. Yet, several of these vaccines despite 
being highly efficient raised concern for their poor tolerability, often caused by 
pathogen intrinsic toxins or a combination of several PAMPs. 
No doubt, vaccines are a powerful tool of preventive medicine. In recent years, the 
progress in vaccine development has been great and the number of lives saved has 
been impressive.  However, these successes arrived but not without failures. A tragic 
example, known as “the Cutter incident” occurred in the 1950s with a polio vaccine. 
The polio virus was identified in 1908 by Karl Landsteiner. At its peak in the 1940s 
and 1950s, polio paralyzed or killed over half a million people worldwide every year 
[55]. In April 1955 more than 200.000 children in the USA received a polio vaccine 
in which the process of inactivating the live virus was defective. Within days there 
were reports of paralysis and the vaccination programme against polio was 
abandoned. Subsequent investigations revealed that the vaccine, manufactured by the 
California-based family firm of Cutter Laboratories, had caused 40.000 cases of 
polio, killing many children or leaving them with varying degrees of paralysis [56]. 
Over the years, the bio-technological advancements have given us laboratory powers 
to better understand disease etiology and produce newer and improved vaccine 
products. The results have been amazing and including the total eradication of 
smallpox and the prevention of many other dangerous infectious diseases.   
Anyway, it is important to remember that the development of a vaccine, from basic 
research, through vaccine preparation and pre-clinical and clinical testing, to actual 
application and disease control, is technically challenging, hard-working, very 
expensive and take up much time. For example, early vaccination against smallpox 
started in the late 1700s while vaccine became widely available by the early 1900s. 
Anyway, it took decades longer to totally eliminate transmission in North America 
and Europe and years more to eliminate it from the rest of the world.  
Recently, more defined vaccines based on partially purified preparations from the 
organism or recombinant subunit proteins have been developed. These types of 
vaccines usually have a better safety profile. However, their development requires 
knowledge of the best target antigens to induce a protective immune response. 
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Importantly, the better safety profile comes at the cost that the highly purified 
antigens, by themselves, are often not sufficiently immunogenic. Therefore, 
adjuvants usually need to be added to these types of vaccines. Moreover, subunit 
vaccines do not have an inherent ability to be delivered to appropriate sites for 
optimal immune stimulation, unlike live attenuated organisms, for example, where 
the natural invasiveness of the pathogen provides effective delivery. Thus, in 
designing new effective and safe vaccines, several key elements are required. First, 
an antigen against which an immune response is targeted. Second, an adjuvant for 
efficient stimulation of the innate immune system and finally, delivery systems to 
target the vaccine to appropriate cells of the immune system to ensure optimal 
stimulation [39].  
The advent of the genomic era led to many changes in vaccinology. The continuing 
advances in genome sequencing technologies and bioinformatics enabled researchers 
to explore a microorganism’s genome for antigen discovery. Microbial genomes 
contain all possible antigens and these are used as the starting point to capture 
information for vaccine development. This process, known as ‘Reverse 
Vaccinology’, was first proposed in 2000 based on the identification of novel 
meningococcal vaccine candidates from the genome sequence of a Neisseria 
meningitidis serogroup B strain [57]. Nowadays, the Structural Vaccinology (SV) 
approach is coming on stream. SV is the evolution of Reverse Vaccinology: a 
genome-based approach combined with structural biology, with the idea that 
protective determinants can be used to selectively engineer the antigens that can be 
re-designed and simplified for inclusion in vaccine combinations. The rational 
structure-based antigen optimization has many goals. Among these are the 
facilitation of industrial-scale production of the antigens combination, a greater 
immunogenicity and safety profile. Structural vaccinology is particularly powerful in 
case of antigenic variation between closely related strains and species and can lead to 
the development of improved vaccines against several pathogens and potentially help 
resolve challenges in manufacturing or efficacy [58]. Anyway, despite the increase in 
our knowledge of the immune system and host-pathogen interactions and despite the 
advent of new technologies, we still lack effective vaccines for many diseases.  
Sometimes the vaccine design may not have been optimal and the vaccine used may 
not have induced the correct type of immune response. For example, antibodies are 
not protective against some intracellular pathogens, and T cell responses may be 
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more effective. Sometimes polarized specific immune responses mediated by CD4+ 
T helper (Th) lymphocytes, based on their profile of cytokine production (type 1 or 
Th1 and type 2 or Th2) are needed. Therefore, the recent emphasis on T cell-
stimulating rather than conventional antibody-inducing vaccines may be really 
helpful in such cases. 
Adjuvants have been identified as crucial factors in order to not only activate the 
immune system, but to steer the responses in the desired direction. Accordingly, the 
choice of adjuvant can affect the nature of antibodies and T cells produced, so a 
careful choice of adjuvant is needed to induce the desired and most appropriate 
immune responses. Moreover, adjuvants and other components may then be added to 
improve the characteristics of the vaccine, such as stability, potency, protective 
efficacy, and the number of doses required. These include delivery systems (e.g. 
emulsions, liposomes, and polymers), and compounds able to direct vaccines to 
specific cells of the immune system [59]. 
 
 
 
1.5 Vaccines adjuvants 
 
Vaccine adjuvants are used to enhance immune responses towards co-administered 
antigens, thereby improving vaccine potency, immunological memory or cross-
protection [2, 3]. Different classes of compounds display adjuvant activity in pre-
clinical models; among them, bacterial products, mineral salts, emulsions, 
microparticles, nucleic acids, small molecules, saponins and liposomes [60, 61]. The 
idea that some materials could improve immune responses was recognized many 
years ago with the work of Ramon and Glenny, who used tapioca and aluminium 
hydroxide to enhance the immune responses of horses or guinea pigs to diphtheria 
and tetanus toxoids [62, 63]. Nowadays, experimental adjuvants range from simple 
molecules such as calcium phosphate (CaPi) to very complex mixtures like 
Incomplete Freund’s adjuvant (IFA) made of a water-in-oil emulsion or Complete 
Freund’s adjuvant (CFA) that additionally includes killed Mycobacteria [64]. IFA is 
a water-in-oil emulsion, which can be mixed with antigens and pattern molecules. 
IFA lacks the bacterial antigens that are present in the complete form and which are 
notorious for the induction of discomforting side effects. Although IFA-antigen 
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emulsions elicit long lasting IgG responses, they also stimulate the activation of T-
cytotoxic and T-helper lymphocytes [65, 66]. In spite of such desired properties, IFA 
is not approved for routine immunotherapy in humans, but is merely used in 
investigational clinical trials. For human vaccines, adjuvants of highly defined 
properties that combine efficacy with complete safety are needed and to date only 
very few compounds are licensed. These include aluminum salts, calcium phosphate, 
oil in water emulsions, virosomes and the TLR4 agonist, monophosphoryl lipid A 
(MPL). Calcium phosphate has previously been shown to be an effective adjuvant in 
man for a number of vaccines, including diphtheria and tetanus toxoids [67], but was 
gradually replaced with alum in 1960s. In addition, there are a large number of 
adjuvants currently in development, aimed at boosting CD4+ helper T cell, CD8+ 
cytotoxic T cell, and humoral immune responses.  
Some of the safest and most efficient adjuvants licensed for human use – like 
aluminium hydroxide and the oil-in-water squalene-based emulsion MF59 - have 
been empirically identified and their mechanism of action is still not fully understood 
[60, 68, 69]. A better understanding of the molecular mechanisms of adjuvanticity is 
needed to develop novel and improved adjuvants based on a more rational design. 
The identification of new molecular targets that further improve vaccine efficacy is 
very important, particularly for primary diseases like tuberculosis, malaria, AIDS 
and other diseases that are waiting for new-generation adjuvants that could overcome 
the current vaccine failures [1]. 
Adjuvants can act in several not exclusive ways to enhance the immune responses 
and to generate effective immunological memory. Many of their effects seem to be 
on antigen-presenting cells such as dendritic cells. Indeed, adjuvants can affect the 
migration, maturation, antigen presentation, and expression of costimulatory 
molecules by  Cs, and these events in turn improve the responses of T and B 
lymphocytes to antigen [3]. This activation of  Cs can occur either directly via 
signaling of PRRs like TLRs. On the other hand,  Cs activation can occur via a 
complex cross-talk with other cell types, both immune and non-immune cells. 
Accordingly, adjuvants are often subdivided in TLR-dependent and TLR-
independent adjuvants (Table 3) [70]. 
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Table 3. TLR-dependent and TLR-independent adjuvants in testing or use in human. Adjuvants 
marked with a green tick are components licensed for human vaccines, while those with a red tick 
have been developed or tested in clinical trials, but are not yet approved. (Source: modified and 
updated from De Gregorio et al., Front Immunol. 2013 [70]). 
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1.5.1 TLR-dependent adjuvants  
Many of the vaccines currently used for human use contain whole attenuated or 
killed microorganisms and therefore PAMPs are present. PAMPs can engage PRRs, 
which act as microbial sensors expressed by  Cs and other leukocytes. Currently, 
many PAMPs by themselves are used as natural vaccine adjuvants, among these for 
example CpG oligonucleotides and MPL. The mechanisms of action of TLR-
dependent adjuvants are well characterized. Indeed, TLR signaling has many effects 
on antigen presentation to  Cs, increase in co-stimulatory molecules and cytokine 
levels, leading to the upregulation of cytokines, MHC class II, and co-stimulatory 
molecules and to the migration of  Cs to the T cell area of lymph nodes. A variety of 
immunostimulatory compounds, including proteins, lipids, carbohydrates, and 
nucleic acids, have been shown to be TLR ligands and are currently being used 
experimentally or in clinical trials as vaccine adjuvant. 
 
 
1.5.2 TLR-independent adjuvants  
In contrast, most conventional adjuvants such as alum, emulsions such as MF59, or 
incomplete Freund’s adjuvant elicit efficient immune responses to vaccine in the 
absence of TLRs. Their mechanism of action is only poorly understood despite their 
broad use [68-70]. Interestingly, the most conventional have a common feature: they 
are particulate compounds known to modulate antigen persistency or antigen uptake 
by DCs and therefore have been generally defined as antigen delivery systems. But it 
is likely that antigen-delivery is not their only mechanism. Probably these 
compounds activate the immune system through pattern recognition receptors and 
signaling machineries different from TLRs. Recently, other intracellular innate 
receptors that sense a variety of immunomodulatory compounds, such as NLRs, 
RIG-like receptors and intracellular DNA receptors, have been demonstrated to 
activate the innate immune responses, and possibly the adaptive immune responses, 
in a TLR-independent manner [71, 72]. It is very important to understand how these 
innate sensors or their downstream signaling pathway(s) mediate the adjuvant-
induced innate and adaptive immune responses in order to develop potent and safe 
vaccine [73]. Among TLR-indipendent adjuvants, aluminum salts are the most 
20 
 
widely used adjuvants in human vaccination. Indeed, although insoluble aluminium 
salt based adjuvants have been used extensively since the early 20
th
 century, only 
recently some significant insights have been gained as to how alum actually works 
[68]. The aluminum-containing adjuvants that are licensed for human use are 
aluminum hydroxide Al(OH)x, commonly known as alum, and aluminum phosphate 
(Al(OH)x(PO4)y in which some hydroxyl groups of Al(OH)x are replaced by a 
phosphate group, and whose precise composition depends on the method of 
preparation [74]. Over the last years it has been shown that three potential 
mechanisms are often cited to explain how aluminum-containing adjuvants increase 
humoral immunity: I) the formation of a depot by which the antigen is slowly 
released to enhance the antibody production; II) the induction of inflammation and 
the subsequent recruitment and activation of antigen presenting cells that capture the 
antigen and III) the conversion of soluble antigen into a particulate form so that it is 
better phagocytosed by antigen presenting cells.  
Injection of alum in mice i.p. or i.m. results in a rapid inflammatory response and 
release of many inflammatory cytokines [75, 76] that attract cells of the innate 
immune system at the injection site. Particularly, IL-1β levels increase few hours 
after injection [77, 78]. IL-1β production is dependent on the activation of myeloid 
differentiation primary response protein 88 (MyD88) and the assembly of the 
NLRP3 inflammasome, and subsequent activation of caspase-1 [78]. However, the 
role of the inflammasome and IL-1β in alum’s activity is controversial [79, 80]. In 
addition, there is the local release of endogenous uric acid and DNA [81- 83], 
probably by local tissue damage at the injection site. In particular, it was shown that 
recruited monocytes take up antigen, process it and re-expose antigen peptides on 
MHCII molecules on their way to the draining lymph nodes while differentiating into 
DCs. In the nodes, mature DCs then activate antigen-specific T cells that 
differentiate into T helper cells. Particularly in the mouse, this response is Th2 based. 
In the spleen, and possibly in the draining nodes, there is also recruitment of Ly6
+ 
monocytes, IL-4
+
 eosinophils that stimulate also B cell responses. In humans, it also 
appears that alum-formulated vaccines mainly act at the level of the monocyte, 
inducing phenotypic and functional maturation [9, 84, 85]. Together, these 
experiments demonstrated that monocyte-derived DCs are necessary to mediate the 
adjuvant effects of alum.  
After aluminum-containing adjuvants, oil-in-water emulsions, such as MF59, are the 
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most common adjuvants licensed for human use. Since MF59 turned out to become a 
particular focus of this work we dedicated a separate chapter to this attractive 
adjuvant formulation. MF59 composition and informations about its mode of action 
are described below in much greater detail.  
 
 
1.5.3 Combination adjuvants  
 
It has been proposed that particulate adjuvants (delivery systems) should be 
combined to TLR agonists to optimize vaccines based on poorly immunogenic 
proteins. Combinations of TLR agonists like CpG, with delivery systems such as 
mineral salts, emulsions, and microparticles are superior to the individual adjuvant 
components in inducing humoral and cellular responses [70, 86]. An example is the 
Adjuvant System 04 (AS04) developed by GlaxoSmithKline that combines the TLR4 
agonist, MPL, and aluminum salt [87]. 
 
 
1.5.4 The TLR-independent adjuvant MF59: mechanism of 
action 
MF59 is an oil-in-water emulsion consisting of squalene (4.3% v/v), and two non-
ionic surfactants tween 80 (0.5% v/v) and span 85 (0.5% v/v), emulsified in citrate 
buffer (10 mM) (Fig. 1). MF59 is a well-established, safe and potent emulsion-based 
vaccine adjuvant that has been licensed since 1997 in more than 20 countries, for use 
in an influenza vaccine for the elderly (Fluad
®
). The overall safety profile of MF59 
has been established clinically through an extensive pharmacovigilance evaluation 
[88]. MF59 consists of small (∼160 nm in diameter) squalene oil droplets stabilized 
by the addition of tween 80 and span85, which are widely used as emulsifiers in 
foods, cosmetics and pharmaceuticals [89]. Squalene is a biosynthetic precursor to 
cholesterol and steroid hormones. Squalene is synthesized in the liver in humans and 
circulates in the bloodstream, but is most abundant in the skin, where it is the main 
component of sebaceous secretions. Moreover, significant quantities of squalene are 
naturally present in adipose tissue, muscles and lymph nodes. Hence, squalene is 
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both biodegradable and biocompatible and is also a normal component of the human 
diet. This was also an important reason for the selection of squalene during the 
development of MF59. An oil that has no inherent biological activity, that is a 
normal component in the human body at the site of administration, and that can be 
easily metabolized and excreted, is of great advantage for safety and tolerability. 
Shark livers provide the natural source of squalene for MF59 while tween 80 and 
span 85 are sourced from plants [9, 61]. 
 
 
    
 
 
Fig. 1. Composition of MF59 emulsion.  A, Sketch of MF59 emulsion and  B, chemical structures of 
its individual components (Source: Calabrò et al., Vaccine 2013 [89]). 
 
 
A 
B 
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Over the years, the mechanism of action of MF59 has been extensively evaluated 
(88-92). Briefly, normal tissue-resident cells like macrophages and muscle cells are 
initially activated by injection of MF59 and are able to induce a local 
immunocompetent environment at the muscle injection site. A mixture of cytokines, 
chemokines and other factors is produced by these cells. The released 
chemoattractants act on immune cells and result in their migration from the blood 
stream into the muscle. The recruited target cells, including monocytes and 
granulocytes, also produce cytokine and chemokines upon contact with MF59, 
thereby further amplifying the chemokine gradient. This mechanism results in signal 
amplification and to a significant influx of phagocytic cells into the injection site. 
The overall higher number of cells available locally increases the chance of 
interaction between an APC and the antigen. Higher numbers of antigen-positive 
APCs lead to a more efficient transport of Ag to the lymph nodes, enhance the 
probability of APCs encounter with antigen-specific T cells and thus result in better 
T cell priming (Fig. 2) [9].  
 
Fig. 2. Model for the mechanism of action of MF59 at the muscle injection site. MF59 creates 
atransient and local immunocompetent environment in the muscle following injection. Target cells are 
activated and a large panel of genes is differentially regulated in response to the adjuvant. Many of 
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these genes code for chemokines and cytokines. An increase in chemokines levels lead to the influx of 
many immune cells from the blood stream into the muscle. Recruited cells can also respond to the 
adjuvant by chemokine secretion thereby creating an immune amplification loop. All recruited cells 
can take up the adjuvant and antigen and transport them to the draining lymph nodes. Thus, MF59 
leads to a much higher number of antigen presenting cells in the lymph nodes where they can interact 
with Ag-specific T cells to start adaptive immune responses. Strong innate immune responses leads to 
enhanced adaptive immune responses which translates to higher numbers of Ag-specific effector and 
memory T cells, such as antibody-titers and finally to greater vaccine potency (Source: Seubert A. et 
al., J. Immunol., 2008 [9]) 
 
 
To understand which cells are a primary target of MF59, different human immune 
cells were cultured in vitro alone or in presence of the adjuvant. Monocytes, 
macrophages and granulocytes were found to be specifically activated by MF59. It 
was demonstrated that they all responded to the adjuvant in a similar manner, by 
producing the following chemokines: MCP-1 (also known as CCL-2), IL-8 (CXCL-
8), MIP-1 (CCL-3) and MIP-1 (CCL-4). In vivo, these chemokines attract mainly 
monocytes and granulocytes, the same cell types that released chemokines in 
response to MF59 exposure in vitro [9]. Accordingly it was postulated that a key 
component of the mechanism of MF59 was chemokine-driven immune cell 
recruitment and chemokine-release that would create a positive feedback loop, 
strongly enhancing the numbers of immune cells at the injection site. These cells 
could then further participate in antigen uptake and transport to the draining lymph 
nodes. 
It was found that monocytes could undergo phenotypical changes upon incubation 
with MF59. The cells adopted a more DC-like phenotype, so it was further 
hypothesized that the MF59 adjuvant induces a monocyte-to-DC differentiation. As 
DCs are considered to be the key antigen presenting cell type which prime naïve T 
cells and initiate adaptive immunity, an increase in numbers of this important cell 
type could translate into an overall higher frequency of immunity initiating cells at 
the injection site, and within the local lymph node. Importantly, the results generated 
in vitro with human cells were consistent with the available data in mice [90], which 
showed mainly monocyte/macrophage recruitment into the injection site, with a 
minor fraction of DCs, probably derived from differentiation rather than direct 
recruitment.  
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Moreover, gene expression profiles induced in the mouse muscle following injection 
of several adjuvants revealed that MF59 leads to upregulation of genes involved in 
immune activation within the muscle after local administration [11]. MF59 was 
found to be a much broader activator of transcriptional changes than other commonly 
used adjuvants such as alum or CpG oligonucleotides [11]. Many of the upregulated 
genes coded for cyto- or chemokines, cytokine receptors, adhesion molecules 
involved in leukocyte migration, and antigen-presentation related genes. It was also 
shown by confocal microscopy that MF59 triggered a more rapid influx of CD11b+ 
cells from blood compared with other adjuvants. Moreover, muscle cells were 
identified as additional potential target cells of MF59. Indeed, muscle cells are 
responsive to the adjuvant by upregulation of the early innate activation markers 
JunB and pentraxin3 (Ptx3) [11]. 
Despite these encouraging results it is still unclear, which signaling pathways and 
immune receptors are triggered by MF59. It has been suggested for several 
adjuvants, such as alum, that their activity depends on the activation of the NLRP3-
inflammasome, which is required for the correct processing of a number of pro-
inflammatory cytokines, including IL-1β. However, MF59 was shown to work in a 
NLRP3-independent manner by two independent groups [91, 92]. Instead it was 
demonstrated that the adaptor molecule MyD88 is crucial for MF59 adjuvanticity 
[91] as well as the apoptosis-associated speck-like protein containing CARD (ASC) 
[92]. Further studies will be necessary to dissect all of the steps of the MF59-induced 
signaling cascades.  
 
 
1.5.5 Danger signals in the mechanism of action of TLRs-
independent adjuvants 
 
The danger theory proposed by Matzinger could explain how particulate adjuvants 
trigger innate and adaptive immunity [20]. Alarmins lost from cells subsequent to 
trauma or infection may serve as local endogenous adjuvants.   
Endogenous danger signals have been linked to adjuvanticity, for example recent 
reports have shown that alum induces tissue damage at the injection site and promote 
the release of endogenous DAMPs. In particular, endogenous uric acid and DNA 
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release are involved in the adjuvanticity of alum [81-83]. Moreover, alum-driven 
DNA release has been implicated in the priming of naïve T cell after the first dose of 
vaccine and has only a partial effect on antibody responses, suggesting that 
additional mechanisms are involved in alum adjuvanticity [83]. However the role of 
extracellular ATP during vaccination has never been explored. As reported above, 
extracellular ATP has many immunomodulatory properties and there are evidences 
of its ability to enhance immunity acting on P2Rs. Monocyte-derived dendritic cells 
have been shown to express a number of P2Rs of both the P2X and the P2Y series 
[93, 94]. Exposure of monocyte-derived dendritic cells to ATP results in up-
regulation of CD54 and MHC class II molecules, induces secretion of IL-12, and 
augments stimulatory capacity for allogeneic T cells [94]. And in combination with 
TNF-α, ATP has been shown to increase the expression of co-stimulatory molecules 
such as CD80, CD83, and CD86 in monocyte-derived dendritic cells [95]. 
Furthermore, the ability of dendritic cells derived from murine fetal skin to present 
antigens was reduced by oxidized ATP, an irreversible inhibitor of P2XRs, and 
clones of dendritic cells selected for lack of P2X7Rs also had decreased Ag-
presenting ability, suggesting a role for this receptor in Ag presentation [93].  
Exogenous administration of a purinergic agonist, ATPγS, can enhance cutaneous 
immunity by augmenting the Ag uptake by APCs. These data demonstrate that ATP 
could work as an endogenous adjuvant and that the release of ATP during infection 
or trauma to the skin may result in enhanced cutaneous immunity suggesting that 
agonists of P2Rs represent a potentially useful class of therapeutic adjuvants [96]. 
Moreover, Denkinger and collegues found that suramin, a small molecular weight 
naphthylurea agonist of P2X/P2Y receptors, has adjuvant properties in vivo. Their 
results suggest that suramin promotes its adjuvant effects via activation of APCs, 
probably through modulation of P2Y or P2X receptors [97]. Therefore as ATP 
triggers a myriad of immunological events we started a project to investigate a 
possible link among the release of ATP at the vaccine injection site and 
adjuvanticity. 
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1.6 Aim of the project 
 
Vaccine adjuvants are also known as “the dirty little secret of immunologists”, a line 
coined by Charlie Janeway. Indeed, despite their effectiveness and their wide use, the 
mechanism of action of many adjuvants is still poorly characterized [2]. Therefore, a 
better understanding of adjuvanticity is needed to develop novel adjuvants based on 
molecular targets that further improve vaccine efficacy. This is particularly important 
for primary diseases for which protective vaccines do not exist [3]. An examination 
of the chemical nature of four major vaccine adjuvants – alum, CaPi, IFA and MF59 
– suggested that they could interact with the phospholipid bilayer of cell membranes, 
via hydrogen bonding or ionic interactions with the head groups of phospholipids/ 
glycolipids and/or via hydrophobic interactions with the hydrocarbon chains of 
lipids. As vaccines are frequently administered by intramuscular injection, we 
posited that: I) a high local concentration of adjuvant is generated in a confined 
portion of the muscle, and that II) the first cell membrane they get in contact with is 
the sarcolemma. Since we found that the muscle injection of membrane interacting 
snake phospholipases A2 (PLA2) myotoxins induces the release of ATP, which is 
contained in large amounts inside muscle fibers [98, 99], we decided to evaluate the 
possibility that other putative membrane interacting agents, such as the major 
adjuvants mentioned above, might similarly induce ATP release. This possibility 
would be particularly relevant in the context of adjuvanticity as ATP is a "danger 
signal" acting on a variety of purinergic P2 receptors and, as such, is a strong 
modulator of immune responses [4-6]. Therefore, we tested the possibility that 
extracellular ATP is involved in boosting the immune response by the 
aforementioned four common adjuvants. 
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2. RESULTS 
 
2.1 Adjuvant-induced ATP release from injected mouse muscles 
 
In order to test our hypothesis, we monitored the adjuvant-stimulated ATP release in 
mice using the reporter system luciferase-luciferin. In the presence of ATP, 
luciferase catalyzes oxidation of luciferin with emission of photons that can be 
recorded by an appropriate imaging apparatus.  
Recent work showed that cells engineered to stably express luciferase on their 
plasma membrane (PmeLUC- cells) are suitable to detect changes in extracellular 
ATP concentration in vivo [100]. However, in preliminary experiments, we found 
that i.m. injected luciferase adsorbs onto muscle fibers in vivo and efficiently reports 
on ATP changes within the muscle. Furthermore, administration of soluble luciferase 
causes a smaller perturbation of tissue homeostasis than injection of the PmeLUC-
cell suspension. This read-out is so sensitive that even the low ATP release due to 
needle injury can be detected at the injection site. Testing the different adjuvants, we 
found that only MF59-injection induces a fast and prominent ATP signal that is 
significantly higher than ATP release caused by PBS injection in the contralateral 
muscle (Fig. 3, A and E). In contrast, CaPi- or IFA-inoculation do not increase ATP 
release over buffer control (Fig. 3, B, C, F, G) and alum even appears to decrease the 
signal (Fig. 1, D and H). Yet, alum readily binds many proteins. Since we observed 
that ATP binds to alum in vitro the luminescence reduction could be a consequence 
of ATP and/ or luciferin-luciferase adsorption onto the adjuvant surface. Quantitative 
photoemission evaluation revealed that MF59-injection increased extracellular ATP 
levels about three fold compared to those triggered by PBS- (CaPi-, IFA- or alum-) 
containing mixtures (Fig. 3, E to H). Extracellular ATP increases within 2-3 min 
following MF59 injection, and then declines over the following 5-6 min. Signal 
decline is most likely due to ATP dilution in tissue fluids and to the ATP-
hydrolyzing activity of ecto-ATPases, which are present on the surface of 
sarcolemma and stromal cells [101]. To test this latter possibility and to have an 
independent evaluation of ATP release, we injected ex vivo tibialis anterior and 
quadriceps muscles with MF59 or buffer control and measured ATP release into the 
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medium (Fig. 3, I and J). The assay confirms prior findings, yet ATP release lasts 
longer, possibly owing to the different diffusion kinetics of the fluids within the peri-
muscle milieu in the two different set-ups. Furthermore, in the ex vivo assay, ATP 
freely diffuses into the bathing solution, and therefore partially escapes hydrolysis, 
indirectly supporting the explanation that in the in vivo experiments ATP is 
immediately exposed to the degrading activity of ecto-ATPases.  
 
 
 
Fig. 3. Adjuvant-induced ATP release in mouse muscles. (A-D): representative images taken 3 min 
after intramuscular injection of adjuvants (right hind limb; asterisk) or PBS (left hind limb) in Balb/c 
30 
 
mice together with the mixture luciferase-luciferin that reports on ATP changes. (E-H) corresponding 
quantitative analyses of chemiluminescence emission over time (number of photons/sec in the region 
of interest). (A and E) MF59 (40% v/v), (B and F) CaPi (50 g), (C and G) IFA (40% v/v), (D and H) 
alum (100 g); (I and J) ATP release from ex vivo mouse muscles injected with MF59. Mouse tibialis 
anterior (I) and quadriceps (J) muscles were exposed and injected with MF59 (40% v/v), continuous 
lines; the dotted line refers to the injection of the same volume of PBS. Muscles were rapidly removed 
and suspended in oxygenated buffer at 37°C. ATP released into buffer was quantified at the given 
time points using the luciferin-luciferase assay and a known ATP standard. Data show mean values + 
SD from at least four independent experiments. Unpaired, two-tailed Student’s T-test (T): * P< 0.05, 
** P< 0.01, *** P< 0.001. 
 
 
MF59 consist of small squalene oil droplets stabilized by the addition of two non-
ionic surfactants, tween 80 and span 85, emulsified in citrate buffer. An examination 
of the chemical nature of MF59 nanoparticles, suggested that they could potentially 
interact with the phospholipid bilayer of cell membranes. In particular the two 
surfactants, located on the particle surface, are putative membrane active agents. We 
tested which of the individual ingredients of MF59 would be responsible for its 
ability to release ATP. Not surprisingly, ATP release is caused by tween 80 and span 
85 but not by squalene oil alone (Fig. 4). 
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Fig. 4. Tween 80 and span 85 are responsible for the MF59-induced ATP release. A-C, 
quantitative analysis of light emission after imaging of BALB/c mice (5 mice/group) i.m. injected 
with (A) tween 80 (0.5% v/v), (B) span 85 (0.5% v/v) or (C) squalene (4.3% v/v) (left leg) and PBS 
(right leg). Chemiluminescence is reported as the number of photons per sec in the region of interest; 
Data show mean values + SD from at least four independent experiments. Unpaired, two-tailed 
Student’s T-test (T): * P< 0.05. 
 
 
 
Taken together, our results clearly document that MF59 displays a unique capacity to 
greatly increase ATP release from injected muscles. To assess whether this ATP 
release would be essential for the adjuvant effect of MF59, we quenched 
extracellular ATP by co-injection of MF59 with apyrase, an enzyme that rapidly 
hydrolyzes ATP to AMP [102]. Figure 5 (panels A and B) shows that apyrase 
completely abolishes the MF59-induced ATP signal. On the basis of this result, we 
could proceed to determine whether co-injection of apyrase would alter induction of 
innate and adaptive immune responses by MF59. 
 
 
 
 
 
Fig. 5. MF59-induced ATP release in mouse muscles and the effect of apyrase (A) representative 
image taken 3 min after intramuscular injection of MF59 (40% v/v) + apyrase (10U; asterisk) or 
MF59 alone (contralateral muscle) and (B) the corresponding quantitative analysis over time. Data 
show mean values + SD from at least four independent experiments. Unpaired, two-tailed Student’s 
T-test (T): ** P< 0.01. 
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2.2 Immune cell recruitment induced by MF59 injection is inhibited 
by apyrase 
 
 
Over the years, ATP has emerged as an important activator and modulator of 
immune responses, among several other danger molecules that are released from 
cells by a variety of pathogens of differing physical, chemical and biological nature 
[5, 6, 103]. In particular, it was shown that ATP released by stressed or dying cells 
promotes recruitment and activation of phagocytes. Therefore, we investigated 
whether and how ATP release could contribute to the activity of MF59.  
The strong adjuvant-effect of MF59 [7, 8] has been ascribed to its capability to 
induce an immunocompetent environment in the muscle, characterized by a rapid 
and transient influx of a large number of CD11b+ immune cells participating in 
antigen uptake and transport to draining lymph nodes [9-11]. To clarify the role of 
ATP in MF59-induced cell recruitment, mice were injected i.m. with MF59 in the 
presence or absence of apyrase. After 24 hours, muscles were harvested and their 
content of neutrophils, monocytes, DCs and macrophages was determined by flow 
cytometry (the gating strategy is shown in Fig. 6). Co-injection of apyrase clearly 
lowered MF59-induced cell recruitment (Fig. 7), indicating that ATP release is in 
part responsible for cell influx. Yet, on the other hand, ATP by itself does not have 
an appreciable effect, which is true for both degradation-sensitive ATP and 
degradation-resistant ATPγS. However, this is not surprising, as the injection of a 
single ATP bolus does not reproduce the graded concentration of extracellular ATP 
that appears to be necessary to support chemotaxis [6, 104]. In addition, MF59 might 
induce the release of additional danger- or damage-associated signals and 
chemotactic factors that may synergize with ATP, as shown for example for 
mesenchymal stem cell responses to CXCL12 and ATP [105, 106]. In favor of this 
hypothesis is also the finding that injection of alum and IFA also resulted in a 
significant recruitment of CD11b+ cells in the injected muscle. Yet, for all adjuvants, 
cell influx was significantly lower as compared to MF59 (Fig. 7E) and reached levels 
similar to mice treated with MF59 and apyrase. At the same time co-injection of 
apyrase did not have any effect on alum- and IFA-mediated cell recruitment, 
consistently with the previous finding that they are not good ATP inducers in the 
muscle (Fig. 3G and H).   
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Fig. 6. Gating strategy of muscle derived cells. Muscle single cell suspensions were prepared and 
analyzed by FACS applying the depicted gating strategy. 
34 
 
 
 
Fig. 7. Co-injection of apyrase reduces immune cell recruitment induced by MF59, but not by 
IFA or alum. (A-D) Groups of mice were injected i.m. with the indicated compounds, at the 
following doses: MF59 (40% v/v), ATP or ATP-γS (5mM), apyrase (Apy) (10U/ leg) or PBS. Single 
cell suspensions of treated muscles were analyzed by FACS 24 h post-injection. Dots show numbers 
of the respective cell type per individual muscle (N ≥4 per group), while black bars indicate arithmetic 
means. (A) Neutrophils, (B) monocytes, (C) macrophages, and (D) dendritic cells (DCs). (E) Groups 
of mice were injected i.m. with the indicated compounds, at the following doses: MF59 (20% v/v), 
IFA (40% v/v), alum (100 g), apyrase (10U/ leg) or PBS, all in presence of Ovalbumin (10 
g/mouse). Numbers of CD11b+ cells are reported, data show mean values + SD from 8-12 
muscles/group. The injection of all tested adjuvants results in a significant recruitment of CD11b+ 
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cells in muscle when compared to PBS-inoculation. Unpaired, two-tailed Student’s T-test (T): * P< 
0.05, ** P< 0.01.  
An important function of adjuvants is to enhance antigen-specific T cell priming and 
the production of antigen-specific, high affinity antibodies by B cells. These 
processes take place in the draining lymph nodes (LNs) and require the presence of 
an antigen. Therefore, we marked the cell types that may serve as major antigen 
vehicles and investigated whether a local ATP release at the muscle injection site 
could modulate antigen uptake and transport to draining lymph nodes. We used 
Ovalbumin-AF647 (OVA) as antigen. After intramuscular injection of different 
adjuvants and labeled OVA, we analyzed the antigen-positive cells in the draining 
inguinal lymph nodes of treated muscle 24 h post injection (Fig. 8). We found that 
only MF59 strongly enhances the number of OVA-positive cells in draining inguinal 
lymph nodes while alum, IFA and ATPγS did not when compared to OVA injection.  
At this timepoint we detected a significant number of OVA-positive B cells and 
different DC subsets in the draining LNs of mice immunized with MF59 (+/- 
apyrase). A lower number of OVA-positive monocytes, macrophages and 
neutrophils are also present.  
Surprisingly, co-injection of apyrase and MF59 reduces the number of antigen 
positive cells and particularly the number of OVA+ B cells induced by MF59 (Fig. 8 
A and B). It is known that free antigen that arrives in draining lymph nodes is 
sequestered by subcapsular sinus macrophages. Antigen-non specific B cells can 
then transport the antigen on their surface deeper into the node and transfer it to 
follicular DCs. The reduction of OVA-positive B cells observed after co-injection of 
MF59 and apyrase could have different reasons: ATP could either directly regulate 
the carrier activity of antigen-non specific B cells or exert effects up-stream on other 
cell types, such as sub-capsular macrophages. Recently, it was reported that ATP and 
products of ATP hydrolysis can modulate B cells functions with different effects on 
naïve and activated B cells such as T cell-B cell interactions  [107]. Therefore we are 
wondering if B cells could be a key component in ATP-mediated signaling during 
vaccination. 
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Fig. 8. Antigen-positive cells in draining inguinal lymph nodes. (A-B) Groups of mice were 
injected i.m. with the indicated compounds, at the following doses: MF59 (20% v/v), IFA (40% v/v), 
alum (100 g), apyrase (10U/ leg) or PBS, all in presence of Ovalbumin (OVA-AF647; 10 
g/mouse). LNs that drain the treated muscle were analyzed by FACS 24 h p.i. to identify specific 
cells types and Ag-content. (A) Values represent the mean of at least 4 LNs for each group. (B) Dots 
show numbers of OVA+ B cells per individual lymph node (N ≥4 per group), while black bars 
indicate arithmetic means.  Unpaired, two-tailed Student’s T-test (T): * P< 0.05.  
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2.3 ATP release contributes to adjuvanticity of MF59 
 
A strong recruitment of immune cells at the injection site leads to enhanced antigen 
uptake and transport to draining lymph nodes, which translates into overall strongly 
enhanced adaptive immune responses [9, 10]. Accordingly, we assessed the impact 
of MF59-induced ATP release on CD4
+
 T helper responses and antibody titers. 
Groups of mice were immunized with an experimental trivalent influenza vaccine 
(TIV) either as plain antigens or together with MF59 in presence or absence of 
apyrase. Control experiments showed that the injection of TIV antigens alone does 
not induce ATP release (Fig. 9).  
 
 
  
 
Fig. 9. The injection of a trivalent influenza vaccine (TIV) alone does not induce ATP release. 
Quantitative analyses of chemiluminescence emission over time (number of photons/sec in the region 
of interest). For each mouse, one leg was injected intramuscularly with a mixture composed of the 
reporter and TIV antigens (0.1 μg each antigen) alone while the contralateral leg was injected with the 
reporter solution plus PBS or TIV antigens adjuvanted with MF59 (20% v/v). Data show mean values 
+ SD from 8-11 mice per experimental condition in independent experiments. Unpaired, two-tailed 
Student’s T-test (T): * P< 0.05. 
 
 
We found that MF59-induced ATP release strongly contributes to adjuvanticity, both 
for T-helper cell responses and vaccine-specific antibody titers. Vaccine-specific T-
helper cells were reactivated by in vitro stimulation of splenocytes from immunized 
38 
 
mice and assessed by FACS for intracellular cytokine expression; gating strategy and 
representative FACS blots are shown in Fig. 10.  
 
 
 
 
Fig. 10. Gating strategy of spleen derived cells. Spleens from 4 mice/group were taken 2 weeks 
after the first immunization and vaccine-specific T helper cells were re-activated by in vitro 
stimulation. CD4+/ CD44+ T helper cells were identified by the depicted gating strategy. Their 
individual cytokine profile was assessed by intracellular cytokine staining and FACS analysis. 
Cytokine producing cells were identified (numbers inside the gate refers to cytokine-positive cells per 
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total CD4+ T cells) and multiple cytokine-expressing cells were calculated by Boolean gating. Shown 
are representative FACS blots from mice immunized with TIV, TIV+MF59 or TIV+MF59+apyrase, 
respectively. 
 
 
 
MF59-adjuvanted vaccine induced high T cell responses already after the first 
immunization, but this effect was completely abolished by co-injection of apyrase 
(Fig. 11A). Similar results were observed after the booster dose (Fig. 11B). MF59 
induced a mixed Th1/ Th2 profile, but apyrase-mediated abrogation of ATP 
signaling had more impact on Th2 (IL4/13+) responses as compared to Th1 (IFN+). 
This is even more evident after the booster vaccination.  
MF59 significantly enhanced antibody titers against all three vaccine antigens as 
compared to TIV alone already after the first vaccination (Fig. 11C) with a mixed 
IgG1/ IgG2 profile (Fig. 12). The prominent adjuvant effect of MF59 not only leads 
to a large increase in total antibody titers, but also increased functional 
hemagglutination inhibition (HI) titers, that are considered a correlate of protection 
for influenza vaccinations (7, 8) (Fig. 11E). Apyrase-co-injection modestly reduced 
the antibody responses induced by the first injection of MF59-TIV. However the 
adjuvant effect of MF59 was still significant (Fig. 11C and E). Only after the booster 
immunization, the apyrase-mediated reduction of total IgG, IgG1 and HI titers 
became highly significant (Fig. 11D, F and Fig. 12).  
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Fig. 11. Co-injection of apyrase inhibits adjuvanticity of MF59 to a trivalent influenza vaccine. 
(A-F) 12 mice/group were immunized twice (4 weeks apart) with a trivalent influenza vaccine (TIV) 
and adjuvants as indicated: MF59 (40% v/v), apyrase (10 U/ leg) and TIV (0.1 μg each antigen). (A, 
D) Spleens from 4 mice/group were taken 2 weeks after each immunization and vaccine-specific 
CD4
+
 T helper cells were re-activated by in vitro stimulation. Their individual cytokine profile was 
assessed by intracellular cytokine staining and FACS analysis. The bars show cumulative numbers of 
vaccine-specific cytokine expressing cells after the first (A) and second (D) immunization, while the 
individual color code indicates the type of cytokines expressed by the respective cells as indicated in 
the figure legend. (C -F) Serum samples were drawn two weeks after each immunization and vaccine-
specific antibody titers were measured. Total IgG antibody titers towards H1N1/California, 
H3N2/Perth, and B/Brisbane after the first (C) and second (D) immunization. Values represent mean 
logarithmic titers (log 10) of 8-12 mice/group + SD. Hemagglutination inhibition titers towards 
H1N1/California after the first (E) and second (F) immunization; values represent means of Log2 
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titers of 8-12 mice/group + SD. Unpaired, two-tailed Student’s T-test (T):  *P< 0.05,** P< 0.01, *** 
P<0.001,**** P<0.0001.  
 
 
 
 
 
Fig. 12. Apyrase reduces vaccine-specific IgG1 levels induced by MF59. (A-D) Mice were 
immunized twice (4 weeks apart) using the different formulations indicated in the abscissae. The 
following doses were used: MF59 (20% v/v), apyrase (10 U/ leg) and a trivalent influence vaccine 
(TIV) (0.1 μg of each antigen). Serum samples were drawn two weeks after both immunizations and 
the H1N1-specific total IgG, IgG1 and IgG2a levels in sera were measured by ELISA after the first (A 
and B) and second (C and D) immunization. Values represent mean logarithmic titers (log 10) of 8 
mice/group + SD. Unpaired, two-tailed Student’s T-test (T):  * P< 0.05, ** P< 0.01, *** P<0.001, 
**** P<0.0001.  
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Similar results were observed using other antigens like ovalbumin (Fig. 13). 
 
 
 
Fig. 13. Co-injection of apyrase reduces ovalbumin (OVA)-specific antibody titers enhanced by 
MF59. (A and B) Mice were immunized twice (4 weeks apart) with endograde OVA and the indicated 
compounds. The following doses were used: MF59 (40% v/v), apyrase (10 U/ leg) and OVA (10 
μg/mouse). Serum samples were drawn two weeks after each immunization and OVA-specific 
antibody titers were measured by ELISA after the first (A) and second (B) immunization. Values 
represent mean logarithmic titers (log 10) of 8 mice/group + SD. Unpaired, two-tailed Student’s T-test 
(T):   ** P< 0.01, *** P<0.001, **** P<0.0001. 
 
 
 
We wondered whether the partial effect of apyrase after the first immunization with 
TIV-MF59 was due to the use of a high dose of adjuvant that cannot be blocked 
entirely. Therefore we titrated down MF59 from 40% (standard dose used here) to as 
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little as 2.5%. At all conditions tested, a significant reduction of antibody titers by 
apyrase was detected after the booster vaccination but not after the first dose (Fig. 
14).  
 
 
 
Fig. 14. Effect of apyrase on antibody responses induced by decreasing doses of MF59. (A-F) 
Mice were vaccinated with a trivalent influenza vaccine (TIV) and different doses of MF59 (20% v/v, 
5% v/v and 2.5% v/v) with or without apyrase (10 U/leg). Serum samples were drawn two weeks after 
each immunization and the total IgG antibody titers towards (A and B) H1N1/California, (C and D) 
H3N2/Perth, and (E and F) B/Brisbane were measured by ELISA after the prime (post 1) and the 
booster vaccination (post 2). Values are the mean of logarithmic titers (log 10) of 8 mice/group + SD. 
Unpaired, two-tailed Student’s T-test (T):  * P< 0.05, ** P< 0.01, *** P<0.001, **** P<0.0001. 
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In summary, our data demonstrate that ATP is required for CD4+ T cell responses 
induced by MF59 and for secondary antibody responses, but not for primary 
antibody responses. 
In order to better dissect the effect of apyrase on MF59 adjuvanticity we performed 
an additional experiment using TIV. One group of mice received two doses of 
MF59+apyrase as before. In the other groups apyrase was added to MF59 only 
during prime or only during boost (Fig. 15).  The group receiving MF59 plus apyrase 
twice had severely reduced Th cell responses after the first and the second 
vaccination as previously shown. Apyrase co-injection only during prime had a very 
significant effect on CD4 T cells responses after the first dose but only modestly 
reduced CD4 T cell frequencies after the second dose. Apyrase added only during 
boost did not have any significant effect on CD4 T cell frequencies (Fig. 15B). 
Antibody titers were significantly reduced in mice that received MF59+apyrase 
either during both immunizations or during the prime (Fig. 15C) while apyrase-
addition during the booster dose had no significant effect.  
Interestingly we did not detect any difference in antibody titers in the group of mice 
that received apyrase twice compared to the mice that received apyrase only during 
the prime. From this experiment, we concluded that the effect of apyrase on antibody 
responses induced by MF59 most likely resulted from an inhibition of T cell priming 
during the first vaccination. 
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Fig. 15. ATP release induced by MF59 is essential during the first vaccination.  Mice were 
immunized as before with a trivalent influenza vaccine (TIV) and adjuvants as indicated. One group 
of mice received two doses of MF59+apyrase while in the other groups apyrase (Apy) was added to 
MF59 only during prime or only during boost. (A, B) Spleens from 4 mice/group were taken 2 weeks 
after each immunization and vaccine-specific CD4
+
 T helper cells were re-activated by in vitro 
stimulation as before. The bars show cumulative numbers of vaccine-specific cytokine expressing 
cells after the first (A) and second (B) immunization, while the individual color code indicates the 
type of cytokines expressed by the respective cells. (C) serum samples were drawn two weeks after 
the second immunization and total IgG antibody titers towards H1N1/California were measured by 
ELISA. Values represent mean logarithmic titers (log 10) of 8 mice/group + SD. Unpaired, two-tailed 
Student’s T-test (T):  * P< 0.05, ** P< 0.01, *** P<0.001, **** P<0.0001. 
 
 
 
To test this hypothesis, we performed adoptive transfer experiments of MF59-primed 
immune cells. We wanted to confirm whether primed T helper cells lead to the 
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greatly enhanced antibody titers at boost or whether other primed immune cell types 
or immune serum contributed to the effect.  
Initially, we evaluated the possibility to transfer adaptive responses induced by 
vaccination to a naïve recipient injecting MF59-primed immune cells. Therefore, 
mice were vaccinated with a TIV plus MF59. Mice were then sacrificed 10 days after 
the prime; spleens and lymph nodes were collected and processed to obtain single 
immune cells suspensions. Cells were then resuspended in PBS and injected i.v. into 
naïve  recipient mice. One group of recipient mice received only PBS as negative 
control. The day after transfer, recipient mice were immunized with TIV plus MF59 
and two weeks after the immunization sera were collected. Fig. 16 shows the total 
IgG antibody titers towards H1N1/California; mice that received MF59-primed cells 
both from spleens and LNs show higher total IgG titers when compared to mice that 
received PBS. Therefore, the priming effect induced by the first immunization with 
TIV plus MF59 can be transferred to naïve recipient mice injecting primed-immune 
cells. 
 
 
 
Fig. 16 MF59-primed immune cells can transfer adaptive responses induced by vaccination to a 
naïve  recipient. Groups of 12 mice were vaccinated with a TIV plus MF59 and then 10 days after 
prime were sacrificed. Spleens and lymphnodes were collected and processed to obtain single immune 
cells suspensions then injected i.v. in naïve recipient mice. One group of recipient mice received only 
PBS as negative control. The day after transfer, recipient mice were immunized with TIV plus MF59 
and two weeks later serum samples were drawn and total IgG antibody titers towards H1N1/California 
were measured by ELISA. Values represent mean logarithmic titers (log 10) of 8 mice/group + SD. 
Unpaired, two-tailed Student’s T-test (T): **** P<0.0001. 
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To identify the role of the different immune cell types and antibodies on the priming 
effect, we separately transferred either I) serum (100 µl), II) whole CD3+ T cells or 
III) B cells from TIV plus MF59 immunized mice (12 mice/group) to naïve recipient 
mice (8 mice/group). CD3
+
 T cell and B cell suspensions were prepared by magnetic 
separation using the MACS cell separation systems (Miltenyi Biotec) and CD3
+
 T or 
B cell isolation kit (Miltenyi Biotec). The adoptive transfer was performed as 
described above. The day after transfer, recipient mice were immunized with TIV 
plus MF59 and two weeks after immunization sera were collected. Fig. 17 shows the 
total IgG antibody titers towards H1N1/California. Mice that received MF59-primed 
CD3+ cells – but not primed B cells or immune serum - show higher total IgG titers 
when compared to mice that received PBS. Therefore, the priming effect induced by 
the first immunization with TIV plus MF59 can be transferred to naïve recipient 
mice injecting primed T cells. Previously, we speculated that a local ATP release 
induced by MF59 is essential during prime, to induce T cell responses that are 
important at the boost for a beneficial effect on antibody titers. Our results from 
adoptive transfer experiments clearly demonstrate the beneficial effect of primed T 
cell on the development of secondary responses after vaccination with a TIV-
adjuvanted with MF59. 
 
 
 
Fig. 17. MF59-primed CD3
+
 T cells are responsible for the priming effect during vaccination 
with a TIV plus MF59. To identify the role of different immune cell types and antibody on priming 
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effect we separately transferred serum (100 µl), whole CD3+ cells and whole B cells from TIV plus 
MF59 immunized mice (12 mice/group) to naïve recipient mice (8 mice/group). The adoptive transfer 
experiment was performed as described above. The day after transfer, recipient mice were immunized 
with TIV plus MF59 and two weeks later serum samples were drawn and total IgG antibody titers 
towards H1N1/California were measured by ELISA. Values represent mean logarithmic titers (log 10) 
of 8 mice/group + SD. Unpaired, two-tailed Student’s T-test (T): ** P<0.01. 
 
 
 
From our experiments we concluded that adjuvant-induced ATP contributes to 
enhanced recruitment of immune cells into the injection site, to enhanced numbers of 
antigen-positive cells in draining lymph nodes – with a special focus of antigen-
positive B cells – and to subsequent T cell priming. Primed CD4+ T cells then exert 
their prominent helper effect during the booster immunization. 
After having dissected the chain of immune events induced by MF59 and the 
contribution of ATP to each individual response, we asked whether the effect of 
apyrase was specific for MF59 or whether it could be extended to other adjuvants 
(Fig. 18). We found that apyrase did not significantly reduce antibody responses 
generated by TIV antigens alone or in combination with IFA and alum, which do not 
stimulate ATP release in the muscle (Fig. 3, C and D). This is true both for primary 
antibody responses after the first dose (Fig. 18A) and secondary responses (Fig. 18B 
and Fig. 19A) as well as for functional HI titers (Fig. 19B). The analysis of T cell 
responses revealed that inhibition of antigen specific Th cells by apyrase is 
predominantly observed in the presence of MF59. Addition of apyrase to TIV 
antigens alone or formulated with IFA resulted in a non-significant reduction of 
vaccine-specific CD4 T cells. However, apyrase significantly reduced CD4 T cells 
induced by TIV formulated in alum (Fig. 18C). Apyrase mediated hydrolysis of the 
baseline level of extracellular ATP induced by injury might be responsible for the 
observed reduction of specific CD4 T cells in the groups that did not receive MF59 
as adjuvant. 
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Fig. 18. Apyrase inhibits antibody responses induced by TIV adjuvanted with MF59, but not 
with alum and IFA. (A-C) 12 mice/group were immunized as before with a trivalent influenza 
vaccine (TIV) and adjuvants as indicated. The following doses were used:  MF59 (40% v/v), IFA 
(40% v/v), alum (100 μg), apyrase (10 U/ leg) and TIV (0.1 μg each antigen). (A, B) Serum samples 
were drawn two weeks after the first (A) or second (B) immunization and total IgG antibody titers 
towards H1N1/California were measured by ELISA. Values represent mean logarithmic titers (log 10) 
of 8-12 mice mice/group + SD. (C) Spleens from 4 mice/group were taken 2 weeks after the first 
immunization and vaccine-specific CD4
+
 T helper cells were re-activated by in vitro stimulation. 
Their individual cytokine profile was assessed by intracellular cytokine staining and FACS analysis. 
The bars show cumulative numbers of vaccine-specific cytokine expressing cells as indicated in the 
figure legend. Unpaired, two-tailed Student’s T-test (T):  * P< 0.05, ** P< 0.01, *** P<0.001, **** 
P<0.0001. 
 
 
  
 
 
Fig. 19. Co-injection of apyrase abrogates adjuvanticity of MF59, but not of IFA. Mice were 
vaccinated with a monovalent influenza vaccine (MIV) and different adjuvants (MF59 20% v/v or 
IFA 40% v/v) with or without apyrase (10 U/leg). (A) Total IgG antibody titers towards 
H1N1/California. Values represent the mean logarithmic titers (log 10) of 8 mice/group + SD. (B) 
Hemagglutination inhibition titers towards H1N1/California; values represent means of Log2 titers 
of 8 mice/group + SD. Unpaired, two-tailed Student’s T-test (T):  * P< 0.05, ** P< 0.01, *** 
P<0.001. 
 
 
 
2.4 ATP by itself has not adjuvant effect 
 
Our results clearly show that ATP release contributes to adjuvanticity of MF59. 
We questioned whether ATP by itself could induce a measurable adjuvant effect. 
Therefore we immunized mice with TIV and different concentrations of ATP or 
the hydrolysis resistant ATP-S (Fig. 20, A to C). As expected, MF59 increased 
total IgG titers in response to all three influenza antigens, whilst ATP co-
administration did not boost antibody responses at any concentration tested. The 
efficient immune modulation by ATP might depend on timely graded and local 
concentrations of ATP and/or on synergies with other alarmins released by MF59 
injection. Probably the injection of ATP does not mimic the localized tissue 
release of ATP and of other factors induced by MF59 in the muscle. 
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Fig. 20. Injection of ATP or ATP-γS does not have any adjuvant effect. Groups of 
mice were immunized twice with a 4-week interval using the different formulations 
indicated in the abscissae. The following doses were used: MF59 (20% v/v), ATP or 
ATP-γS (1mM and 5mM) and a trivalent influence vaccine (TIV) (0.1 μg of each 
antigen). Serum samples were drawn two weeks after the second immunization and the 
total IgG antibody titers towards (A) H1N1/California, (B) H3N2/Perth, and (C) 
B/Brisbane were measured by ELISA. Values are the mean of logarithmic titers (log 10) 
of 8 mice/group + SD. Unpaired, two-tailed Student’s T-test (T):  *** P<0.001. 
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2.5 Muscle cells could be the main target of MF59 
Previous studies have indicated that MF59 injection induces activation of muscle 
fibers, as revealed by JunB translocation and Pentraxin 3 expression [11], 
suggesting that skeletal muscle fibers, with their high content of ATP, are a major 
target of MF59. To further investigate this possibility we assessed effects of 
MF59 on murine skeletal muscle C2C12 myotubes in culture. We found that 
MF59 induces a very rapid release of ATP from myotubes within minutes, in 
agreement with our data in vivo and ex vivo (Fig. 21 A). eATP targets P2 
receptors. An important consideration is that the purinergic receptors of the P2X 
family are cation-selective channels [108]. ATP binding to a P2X receptor opens 
the channel and allows the transmembrane passage of K
+
, Na
+
, and Ca
2+
 along 
their concentration gradients [4,17]. As purinergic receptors are present in murine 
muscle cells [109, 110] this led us to consider the possibility that ATP released by 
muscle cells may bind to neighboring cells with a consequent alteration of the 
permeability of sarcolemma to ions. As ions flux/exchange across membranes 
modulate immune responses, we investigated these phenomena. Here, we show 
that MF59-treated myotubes rapidly release potassium. It would be interesting to 
evaluate a possible role of ATP in MF59-induced potassium efflux (Fig. 21 B). A 
very fast K
+
 and ATP release from myotubes suggests that MF59 induces a rapid 
alteration of the permeability of sarcolemma. Recently, it was found that a 
cytosolic K+ efflux is sufficient to activate the NLRP3 inflammasome by bacterial 
toxins and particulate matter [111]. As MF59 works independently from NLRP3 
inflammasome activation [91, 92] we propose that other events triggered by ATP 
and ions exchanges are required for its adjuvanticity. 
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Fig. 21. MF59 induces release of ATP and K+ from murine C2C12 muscle cells. (A, B) Cells 
were incubated with MF59 or PBS diluted in DMEM to a final dose of (50% v/v). At the indicated 
timepoints cells were rapidly washed twice with a choline buffer and then lysed in 120 μL of the 
same buffer containing 0.5% (w/v) of Triton X100. (A) Time course of ATP release in medium. 
Points are the average of values obtained in three different experiments ± SD. (B) The amount of 
intracellular K+ is reported, K+ levels are expressed as ppm (parts per million) normalized to the 
corresponding protein content (evaluated by BCA assay); values are the mean of 3 independent 
experiments + SD.   
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3. DISCUSSION 
 
Taken together, our results provide strong evidence that ATP released from 
injected muscle is a crucial contributor to the adjuvant activity of MF59. The 
immunological step in which ATP is required is naïve T cell priming following 
the administration of the first dose of vaccine. Efficient T cell priming is required 
for an optimal antibody response after the boost. Our results from adoptive 
transfer experiments clearly demonstrate the beneficial effect of primed T cell on 
the development of secondary responses after vaccination with a TIV-adjuvanted 
with MF59. The effect of apyrase was more evident for CD4+ T cell responses in 
the Th2 compartment. Accordingly, we observed a strong reduction of IgG1 
antibodies after the booster dose of MF59-TIV vaccine.  
The data available at this stage do not address directly the question concerning 
which cells release ATP around the injection site. However, our preliminary 
results on C2C12 myotubes strongly suggest that skeletal muscle fibers, with their 
high content of ATP, are a major target of MF59 in agreement with previous 
studies that have indicated that MF59 injection induces activation of muscle fibers 
[11]. At variance from MF59, neither alum nor CaPi and IFA were found to 
increase ATP release from muscles over injection-induced background level. 
However, this negative result leaves open the possibility that other "danger 
signaling" molecule(s) could be involved in their adjuvant activities. Indeed, 
recent reports have implicated endogenous uric acid and DNA release in the 
adjuvanticity of alum [81- 83]. Similarly to the role of ATP for MF59, alum-
driven DNA release has been implicated in the priming of naïve T cell after the 
first dose of vaccine and has only a partial effect on antibody responses, 
suggesting that additional mechanisms are involved in alum adjuvanticity [78, 
79]. Even in the case of MF59, the results presented here indicate that ATP is a 
crucial contributor, but not the sole factor involved in MF59 adjuvanticity. 
Exogenous ATP is active on an array of purinergic receptors that can modulate 
intracellular signaling. In particular, ATP is known to activate the NLRP3 
inflammasome complex via the P2X7 receptor, inducing the maturation and 
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release of pro-inflammatory cytokines such as IL-1β [17, 32]. Interestingly, 
NLRP3 has also been linked to alum mechanism of action [78- 80] and therefore 
P2X7 may represent an obvious link between ATP and adjuvanticity. However, 
two independent studies have shown that the mechanism of MF59 is independent 
from NLRP3 inflammasome activation [91, 92] and therefore we propose that 
other events triggered by purinergic receptors are required for adjuvanticity. We 
have reported that MF59 adjuvanticity depends on signaling pathways that 
involve the protein MyD88 [91]. MyD88 is a common adaptor of most Toll like 
receptors (TLRs) and of IL-1 family cytokine receptors such as IL-1R, IL-18R or 
the IL-33R ST2. As MF59 does not trigger TLR signaling in vitro, it is more 
likely that MyD88 signaling downstream of IL-1 family receptors could be crucial 
for MF59 activity. Interestingly, it was shown that ATP-induced signaling via 
purinergic receptors does not only lead to inflammasome-dependent IL-1 release, 
but can also induce the inflammasome-independent release of IL-33 [112]. 
Recently it was shown that P2X7 receptor positively regulates MyD88-dependent 
NFB activation and inflammatory signaling pathways [113]. It would be 
interesting to explore whether the strong adjuvant activity of MF59 is 
compromised in P2X7 KO mice. Additionally, it would be interesting to ascertain 
whether apyrase treatment in MyD88 KO mice might lead to total abrogation of 
all hallmarks of MF59 action, including generation of an immunocompetent 
environment, cell recruitment, antigen uptake, translocation and activation of 
adaptive immunity.  
Furthermore, the specific reduction of OVA-positive B cells observed in the 
draining LNs after co-injection of MF59 and apyrase remains to be elucidated; 
different reasons could explain this phenomenon: ATP could either directly 
regulate the carrier activity of antigen-non specific B cells or exert effects up-
stream on other cell types, such as sub-capsular macrophages. Confocal 
fluorescence microscopy of the draining lymph node at different times after 
injection could help us to elucidate how ATP-mediated pathways take part on the 
aforementioned immunological events. 
Moreover, it would be fascinating to shed light on the molecular pathways 
modulated by ATP after vaccination with MF59, for example by performing 
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microarray analysis of the whole muscle injected with MF59 with or without 
apyrase. 
This work supports the model that adjuvanticity involves induction of host 
molecules acting as danger signals and propose a new model for the mechanism 
of action of MF59 (Fig. 22). The latter activate the immune system to the 
advantage of a more sustained and protective immune reaction to vaccines.  
 
 
 
 
 
Fig. 22. New hypothetic model for the mechanism of action of MF59. Vaccination with MF59 
induces a local release of endogenous danger signals, such as ATP and K+ and the production of 
cytokines and chemokines. These agents working together create a transient and local 
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immunocompetent environment at the muscle injection site. An increase in chemokines [9, 10] and 
ATP levels in the extracellular compartment leads to the influx of many immune cells from the 
peripheral blood into the muscle. Recruited cells can also produce chemokine creating an immune 
amplification loop. All recruited cells can take up the antigen and transport it to the draining lymph 
nodes to induce adaptive immune responses.  We found that the MF59-induced ATP release is 
required for APCs recruitment, Ag uptake and transport to draining LNs. At last, but not least we 
found that ATP-mediated pathways are required for naïve T cell priming following the 
administration of a first dose of a trivalent influenza vaccine. These strong innate immune 
responses induced by MF59 translates into a higher numbers of Ag-specific effector T cells, such 
as antibody-titers and finally to greater vaccine potency. Our data demonstrate for the first time 
that a transient ATP release is required for innate and adaptive immune responses induced by 
MF59 although ATP-mediated pathways remain to be explored. 
 
 
These findings lead to a large area of investigation to identify compounds that 
induce the most appropriate and advantageous danger signals boosting immune 
response to vaccines. We could show that ATP can contribute to a broad panel of 
immune events ranging from innate immunity to adaptive humoral and cellular 
responses, representing an attractive target to improve vaccine responses.  
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4. MATERIALS & METHODS 
 
4.1 Mice 
 
Pathogen-free BALB/c mice (purchased from Charles River) aged 6-8 weeks were 
used in this study in agreement with institutional and European guidelines. All 
experimental procedures involving animals were carried out in accordance with 
the Italian Animal Welfare Act and were approved by the local authority 
veterinary service at the University of Padova, Ferrara and at the Animal Ethical 
Committee of Novartis in Siena. 
 
4.2 Adjuvants 
 
MF59, a Novartis proprietary oil-in-water emulsion consisting of 4.3% (v/v) 
squalene, 0.5% (v/v) tween 80, 0.5% (v/v) span 85 in citrate buffer (10 mM), was 
prepared by homogenization at 12,000 psi with a Microfluidizer (model 110Y; 
Microfluidics, Newton, MA). The emulsion was sterilized and stored at 4 °C. The 
mean particle size of the emulsion droplets determined with a Mastersizer X 
(Malvern Instruments) was 194 ± 76 nm. Aluminium hydroxide was from 
Novartis, calcium phosphate from Brenntag Biosector, and Incomplete Freund's 
Adjuvant from Difco Laboratories. All tested adjuvants were diluted in PBS. 
 
4.3 In vivo bioluminescence imaging 
 
In vivo bioluminescent imaging was performed with an ultra low-noise, high 
sensitivity cooled CCD camera mounted on a light-tight imaging chamber (IVIS 
Lumina System, Caliper, Perkin Elmer). Tracking, monitoring and quantification 
of signals were controlled by the acquisition and analysis software Living Image. 
Mice were anesthetized with a continuous flux of isoflurane, positioned in the 
instrument chamber and injected with a 50 µl syringe fitted with a 29 gauge 
needle (Hamilton). For each mouse, one leg was injected i.m. with a mixture 
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composed of the reporter (luciferase-luciferin mix, Promega) and of the adjuvant 
to be tested: MF59 (40% v/v), alum (100 µg), CaPi (50 µg), and IFA (40% v/v), 
in a total volume of 20 µl. The individual components of MF59 (squalene, Span 
85 and Tween 80) were formulated in PBS at the same dose as within the MF59 
emulsion.  The contralateral leg was injected with the reporter solution plus the 
PBS used for adjuvant dilution. One mouse per each experimental run was 
monitored immediately after injections; luminescent images were obtained with 
constant exposure time periods of 3 minutes for a total of 9 minutes; regions of 
interest were defined manually around the injection site to determine the total 
photon flux as number of photons/second. Experiments with apyrase were 
performed in the same conditions: for each mouse, one leg was injected with a 
mixture composed of the luciferase-luciferin mix plus MF59 (40% v/v) and 
apyrase (10U, Sigma) while the contralateral leg was injected with the reporter 
solution plus MF59 (40% v/v) alone. For all injections the final volume was 20 µl. 
 
4.4 Muscle isolation and ex vivo ATP measurement 
 
Mouse hind limb muscles (tibialis anterior, or quadriceps) were injected with 25 
µl of MF59 (40% v/v) diluted in PBS in one leg or with the same volume of PBS 
in the contralateral one and then rapidly isolated from mice and immediately 
transferred to vials containing 1 mL oxygenated (95% O2, 5% CO2) physiological 
buffer (139 mM NaCl, 12 mM NaHCO3, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 
1 mM KH2PO4, and 11 mM glucose, pH 7.4) at 37 °C. The ATP released in the 
buffer was determined with the ATPlite
TM
 luciferase assay (Perkin-Elmer). 
Briefly, the supernatant of control and treated muscles were collected at the 
indicated timepoint in a white 96-well plate, and mammalian lysis solution was 
added. The plate was shaken for 5 min at 700 rpm at RT. ATP substrate solution 
was added and a 5-min shake was performed in the dark. After 10 min, the 
luminescence was measured by Fluoroskan Ascent FL (Thermo Electron 
Corporation). ATP concentration was calculated from a calibration curve obtained 
using ATP standard solutions. 
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4.5 Cell recruitment into muscle, Ag-uptake and transport to 
draining lymph nodes 
 
Groups of mice were injected with 25 μl/ muscle of either MF59 (40% or 20% 
v/v), alum (100 µg), and IFA (40% v/v), all with or without apyrase (10U/ 
muscle), with ATP-γS or ATP (5mM, Sigma), or PBS buffer control. Experiments 
were performed injecting either adjuvants alone or in presence of the model 
antigen ovalbumin (OVA-AF647; Molecular Probes, Invitrogen). 24 h post-
injection, mice were sacrificed and quadriceps muscles were harvested and 
processed to obtain single cell suspensions. Briefly, muscles were placed into 
tissue culture dishes containing HBSS (Gibco) on ice. The muscles were cut into 
small pieces and digested with 0.05% type II collagenase (Worthington 
Biochemicals) in HBSS for 30 min at 37 ◦C under agitation. The cell suspension 
was centrifuged, resuspended in DMEM (Gibco) and filtered through a 70 μm 
nylon mash (Becton Dickinson). Cells were stained with Live/Dead Fixable 
Yellow (Invitrogen) and combinations of the following antibodies: -Ly6C-FITC, 
-CD11b-PE-Cy7, -Ly6G-PE, -CD3-PerCPCy5.5 (all from BD Pharmingen) 
and -I-A/I-E-AlexaFluor700, -F4/80-PacificBlue, -CD11c-APC-eFluor780 
(all from eBioscience). The stained cells were analyzed using a FACS LSR II 
Special Order System (BD Biosciences) using BD DIVA software (BD 
Biosciences). For Ag-uptake studies and transport to draining lymph nodes mice 
were injected i.m. as above with MF59 (40% v/v), alum (100 µg), IFA (40% v/v), 
all with or without apyrase (10U/ muscle), ATP-γS (5mM, Sigma), or PBS buffer 
control, all in presence of fluorescently labeled ovalbumin (OVA-AF647). Then, 
24 h p.i. lymph nodes were collected, cut into small fragments and digested with 
collagenase D (0.8 mg, Roche) and DNase I (0.25 mg, Roche) in HBSS (Gibco) 
medium for 30 min at 37 °C under continuous agitation. Digested fragments were 
filtered through a 70 μm nylon mash, stained with fluorescently labeled antibodies 
as described above for muscle cell suspensions and analyzed by FACS. 
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4.6 Vaccine formulation and immunization 
 
Experimental trivalent influenza vaccine composed of equal amounts of 
hemagglutinin (HA) from influenza strains H1N1 A/California/7/2009, H3N2 
A/Perth/16/2009 and B/Brisbane/60/2008 was used in immunogenicity 
experiments. The vaccine contains purified subunit antigens and is standardized 
for HA content by single-radial-immunodiffusion. For adjuvanticity experiments, 
groups of eight to twelve animals were immunized two times on days 0 and 28 in 
the quadriceps muscles of both hind legs with 25 μl vaccine/leg (50 μl total per 
mouse). Doses were 0.3 μg (0.1 μg each antigen) of either influenza soluble 
trivalent egg-derived antigen alone; antigens mixed with research grade MF59 
(40% v/v), alum (100 µg) or IFA (40% v/v), all with or without apyrase (10 U/ 
muscle), apyrase alone, ATP- ATP (1 mM or 5 mM). Serum samples of 
individual mice were collected 2 weeks after each immunization and evaluated for 
total immunoglobulin G (IgG) antibody titers by ELISA and hemagglutination 
inhibition (HI) titers by the hemagglutination inhibition assay. All formulations 
were optimized for pH and osmolality to physiological conditions. For some 
experiments, mice were immunized as described before with 10 µg/mouse 
Endograde ovalbumin (Hyglos). 
 
4.7 ELISA 
 
Serum samples were obtained two weeks after the first and second immunization 
and Ag-specific total IgG, IgG1 or IgG2a measured by ELISA. For flu specific 
ELISA, MaxiSorp plates (Nunc) were coated with 2 µg /ml of each antigen 
(H1N1 California, H3N2 Perth, B Brisbane) in PBS overnight at 4 ◦ C.  For OVA-
specific ELISA, we used MaxiSorp plates (Nunc), coated with 50 μg/ml of OVA 
(Hyglos) in coating buffer (Na2CO3/NaHCO3, pH 9.6) overnight at 4°C. Plates 
were washed three times with 0.05% Tween in PBS and then blocked with FC 
Blocking (Candor Bioscience) for 2 h at RT, then washed as before and incubated 
for 1 h at RT with individual mouse sera. Plates were washed and incubated for 2 
h at RT with secondary anti-mouse total IgG (Sigma). Plates were washed and P-
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nitrophenyl phosphate disodium (Sigma) added. After 30 minutes the reaction was 
blocked with EDTA (3%, pH 8). Color reaction was measured with SpectraMax 
(Molecular Devices) reader by determining OD at 405 nm. The titers were 
normalized with respect to the reference serum assayed in parallel.  
 
4.8 Determination of antibodies by Hemagglutination Inhibition 
assay 
 
The Hemagglutination Inhibition (HI) assay was carried out on individual sera 
taken 2 weeks after the second immunization. Sera were pretreated with DENKA 
receptor destroying enzyme (RDE, Biogenetics) in a 1:3 volume ratio for 18 h at 
37°C. Samples were inactivated at 56°C for 30 min and stored at 4°C until use. 
Before use the virus antigen was titrated using a 50 μl serial tenfold dilutions of 
the stock vial. The virus working dilution (i.e. dilution factor to reach 4 
Hemagglutinating Units (HAU) in a 25 μl volume) was calculated by dividing by 
8 the previously determined stock titer, and was checked daily before the assay by 
the 4 units test. Twofold serial dilutions of 25 μl pretreated sera and positive 
control sera were treated with 25 μl of virus working dilution. After gentle shake, 
samples were incubated at room temperature for 60 min. 50 μl of turkey red blood 
cells suspension were dispensed in each well and plates were again incubated RT 
for 60 min. The test endpoint was determined by visual inspection for an 
agglutination reaction: a red dot formation indicated a positive reaction 
(inhibition), whereas a diffuse patch of cells a negative reaction 
(hemagglutination). The titer was defined as the highest serum dilution at which 
hemagglutination was inhibited, and the antibody concentration corresponds to the 
reciprocal value of the titer.  
 
4.9 In vitro re-stimulation of antigen-specific CD4
+
 T cells 
 
Four mice per group were sacrificed 2 weeks after each immunization and spleens 
were collected to assess the frequency and phenotype of Ag-specific CD4
+
/CD44
+
 
T cells induced by vaccination. Spleens were processed to obtain single cell 
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suspensions, red blood cells lysed and the splenocytes cultured in RPMI (Gibco) 
containing 10% FCS (HyClone), beta-mercaptoethanol and antibiotics. 2 x 10
6 
splenocytes/well were stimulated in the presence of α-CD28 antibody (1 μg/ml) 
(Becton-Dickinson) and trivalent influenza antigens (1 μg/ml each Ag; total 3 
μg/ml), or with α-CD28 alone (negative control, <0.1% total cytokine-positive 
cells), or with α-CD28 plus α-CD3 (0.1 μg/ml) as positive control (Becton-
Dickinson). After overnight stimulation, Brefeldin A (2.5 μg/ml)(Sigma–Aldrich) 
was added for additional 4 h to inhibit cytokine secretion. Cells were washed and 
stained with Live/Dead Fixable Yellow Dead Cell Stain Kit (Invitrogen). Cells 
were fixed, permeabilized, and stained with the following mAbs: α-CD8-
PETexasRed (Invitrogen); α-CD3-PerCP-Cy5.5; α-CD44-v450; α-CD4-V500; α-
TNF-α- AlexaFluor700; α-IFNγ-PE; and α-IL-2-APC (all Becton-Dickinson) α-
IL-4-FITC; α-IL-13-FITC (e-Bioscience). Cells were then acquired using a FACS 
LSR II Special Order System (BD Biosciences) and data were analyzed using 
FlowJo software (Tree Star). For each individual mouse, frequencies of influenza-
specific T cells were calculated by subtracting the background measured in the 
corresponding negative control for each cytokine.  
 
4.10 Adoptive transfer  
 
Groups of 12 mice were vaccinated with a trivalent influenza vaccine (TIV) plus 
MF59 and then 10 days after prime were sacrificed. Spleens and lymph nodes 
were collected and processed to obtain single immune cells suspensions then 
injected i.v. in naive recipient mice. One group of recipient mice received only 
PBS as negative control. The day after transfer, recipient mice were immunized 
with TIV plus MF59 and two weeks later serum samples were drawn to evaluate 
vaccine-specific total IgG antibody titers. We verified that MF59-primed immune 
cells could transfer adaptive responses induced by vaccination to a naive recipient 
mice. Therefore, to identify the role of different immune cell types and antibodies 
on priming effect we separately transferred serum (100 µl), whole CD3+ cells (T 
cells) and whole B cell from TIV plus MF59 immunized mice (12/group) to naive 
recipient mice (8/ group). Spleens and lymph nodes were processed to obtain 
single immune cells suspensions. CD3
+
 cells and B cells suspensions were 
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prepared by magnetic separation using an autoMACS (Miltenyi Biotec) and CD3
+
 
T or B cell isolation kit (Miltenyi Biotec). Cells or sera were resuspended in PBS 
and injected i.v. in naive mice. One group of recipient mice received only PBS as 
negative control. The day after transfer, recipient mice were immunized with TIV 
plus MF59 and two weeks after immunization sera were collected to evaluate 
vaccine specific antibody titers.  
 
4.11 C2C12 cell cultures 
 
Murine skeletal muscle C2C12 cells were obtained from the American Type 
Culture Collection (CRL-1772; ATCC), and were maintained at subconfluent 
levels in DMEM (Gibco) supplemented with 10% FBS (EuroClone). To induce 
differentiation (5–6 d), cells were grown to 80% confluence and then the medium 
was replaced with DMEM supplemented with 2% equine serum (Gibco) and 
changed every 24–48 h.  
 
4.12 Potassium measurement 
 
Cell were incubated with MF59 or PBS diluted in DMEM to a final dose of (50% 
v/v). At the indicated timepoint cells were rapidly washed twice with a choline 
buffer (129 mM CholineCl, 1.5 mM CaCl2, 0.8 mM MgCl2, 5 mM H3PO4, 5 
mM citric acid, and 5.6 mM glucose, pH 7.4) and then dissolved in 120 μL of the 
same buffer containing 0.5% w/v of Triton X100. Samples were diluted in 
bidistilled water and the K+ content was measured by flame photometry with a 
Perkin-Elmer Analyst atomic absorption photometer. K+ levels for each sample 
are normalized to the corresponding protein content evaluated by BCA assay. 
 
4.13 Statistical analysis 
 
All statistics were performed using GraphPad Prism software. The unpaired two-
sample Student’s T-test was used. P values less than 0.05 were considered 
significant.  
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6. APPENDIX 
 
6.1 Abbreviations 
 
(Al(OH)x(PO4)y, the chemical formula for aluminium phosphate 
Ab, antibody 
ADP, adenosine 5'-diphosphate 
AF, alexa fluor 
Ag, antigen 
AIDS, acquired immunodeficiency syndrome 
Al(OH)x, the chemical formula for aluminium hydroxide 
Alum, aluminium hydroxide ( in this context) 
AMP, adenosine 5'-monophosphate 
APCs, Ag-presenting cells 
APY, apyrase 
AS, Adjuvant sistem (as AS01,AS02, AS03, AS04) 
ASC, apoptosis-associated speck-like protein containing CARD 
ATP, adenosine triphosphate 
ATPγS, adenosine 5′-O-(3-thio)triphosphate  
B, influenza strain B/Brisbane/60/2008 
BALB/c, a mouse strain 
BCA, bicinchoninic acid  
C2C12, a mouse myoblast cell line 
CaPi, calcium phospate 
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CARD, caspase activation and recruitment domain 
CCL, C-C motif chemokine ligand (as CCL-2) 
CCR, C-C motif chemokine receptor 
CD, Cluster of Differentiation (as CD4, CD8, etc.) 
CFA, complete Freund's adjuvant 
CpG, cytosine guanine dinucleotide 
CTL, Cytotoxic T Lymphocytes 
CXCL, CXC chemokine ligand 
DAMPs, danger-associated molecular patterns  
DCs, dendritic cells 
DMEM, Dulbecco's modified Eagle's medium 
DNA, deoxyribonucleic acid 
DNase, deoxyribonuclease 
ds, double-stranded (as dsDNA or RNA) 
eATP, extracellular ATP 
EDTA, ethylenediaminetetraacetic acid 
ELISA, enzyme-linked immunosorbent assay 
FACS, fluorescence-activated cell sorter 
FBS, fetal bovine serum 
FCS, fetal calf serum 
FITC, fluorescein isothiocyanate 
h, hour (only with numbers) 
H1N1, influenza strain H1N1 A/California/7/2009 
H3N2, influenza strain  H3N2 A/Perth/16/2009  
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HA, hemagglutinin 
HBSS, Hanks' balanced salt solution 
HI, hemagglutination inhibition 
HIV, human immunodeficiency virus 
HMGB1, high- mobility group box protein 1 
i.m., intramuscular 
i.p., intraperitoneal 
i.v., intravenous 
IFA, incomplete Freund's adjuvant 
IFN, interferon (e.g., IFN-γ) 
Ig, immunoglobulin (also IgA, IgD, IgE, IgG, IgM) 
IL, interleukin (e.g., IL-2) 
IPAF, ICE protease-activating factor 
K+, potassium 
LNs, lymph nodes 
LRR, leucine-rich repeat 
mAb, monoclonal Ab 
MACS, magnetic-activated cell sorting 
MCP, monocyte chemoattractant protein 
MHC, major histocompatibility complex (as MHCI, MHCII) 
min, minute (only with numbers) 
MIP, macrophage-inflammatory protein 
MIV, monovalent influenza vaccine 
ml, milliliter (only with numbers) 
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mM, milliMolar (only with numbers) 
MPL, monophosphoryl lipid A 
MyD88, myeloid differentiating factor 88 
N, number in study or group 
n.s., not significant 
NAIP, NLR family, apoptosis inhibitory protein 
NALPs, NACHT-LRR and pyrin domain-containing protein 
NLRP3, Nod-like receptor family, pyrin domain-containing 3 
NLRs, nucleotide-binding oligomerization domain (NOD)-like receptors 
NOD, nucleotide-binding oligomerization domain 
OD, optical density 
OVA, ovalbumin 
P, p-value 
p.i., post injection 
P2Rs, P2 receptors 
P2X, subclasse of P2 receptors (ligand‑gated cation channels) e.g. P2X7 
P2Y, subclasse of P2 receptors (G protein‑coupled receptors) 
PAMPs, pathogen-associated molecular patterns  
PBS, phosphate-buffered saline 
PE-Cy7, phycoerythrin-Cyanin 7 
PE, phycoerythrin 
PerCP, peridinin chlorophyll protein 
PerCPCy5.5,  PerCP- cyanine 5.5 
PLA2, phospholipases A2 
79 
 
Post 1, post first immunization 
Post 2, post second immunization 
PRRs, pattern-recognition receptors  
Ptx3, pentraxin 3 
QS, Quillaja Saponaria (as QS21) 
R, receptor (e.g., IL-2R) 
RIG, retinoic acid-inducible gene  
RLHs, retinoic acid-inducible gene (RIG)-like helicases like receptors (controllala) 
RNA, ribonucleic acid 
ROS, reactive oxygen species 
RPMI (usually RPMI 1640) 
RT, room temperature 
s, second (use only with numbers) 
SD, standard deviation 
SV, structural vaccinology 
Th cell, T helper cell (as Th1, Th2) 
TIV, trivalent influenza vaccine 
TLRs, Toll-like receptors 
TNF, tumor necrosis factor (as TNF-α) 
U, unit (only with numbers) 
UTP, uridine 5'-triphosphate 
v/v, volume to volume ratio (%) 
w/v, weight to volume ratio (%) 
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